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“Le microbe n’est rien, 
le terrain est tout!”
Louis Pasteur, 
sur son lit de mort (1895)
4
CONTENTS
1 ABSTRACT   6
2 PUBLICATIONS  8
3 ABBREVIATIONS  9
4 INTRODUCTION  11
5 REVIEW OF THE LITERATURE 13
 5.1 Immunity in the upper respiratory tract 13
 5.2 Innate immunity 16
  5.2.1 Cellular innate immunity 16
  5.2.2 Complement activation and regulation 18
  5.2.3 Complement function and deficiencies 19
  5.2.4 Complement evasion by pathogens 21
   5.2.4.1 Complement evasion by group A streptococci 23
  5.2.5 Innate immunity in adenotonsillar tissue  25
 5.3 Adaptive immunity  26
  5.3.1 Cellular adaptive immunity 26
  5.3.2 Humoral immunity 27
   5.3.2.1 Immunoglobulins 28
   5.3.2.2 IgM, IgA and IgD 28
   5.3.2.3 IgG and IgG subclasses 29
   5.3.2.4 IgG subclass deficiencies 30
   5.3.2.5 IgE and allergy 31
 5.4 Upper airway diseases 34
  5.4.1 Sinonasal disease definitions 34
  5.4.2 Rhinosinusitis in adults 34
  5.4.3 Nasal polyposis 36
  5.4.4 Airway allergy 38
  5.4.5 Tonsillar diseases in children 38
 5.5 The role of sex in immunity and respiratory diseases 40
  5.5.1 Innate immunity 40
  5.5.2 Adaptive immunity 41
  5.5.3 Allergic diseases 41
  5.5.4 Respiratory infections 42
   5.5.4.1 Sinonasal infections 42
   5.5.4.2 Tonsillar infections 42
 5.6 Rhinoviruses 44
6 AIMS OF THE STUDY 47
7 SUBJECTS AND METHODS 48
 7.1 Study subjects and ethical considerations 48
 7.2 Bacterial strains 49
 7.3 Data collection and definitions 49
 7.4 Sample collection, processing and storage  51
 7.5 Analytical methods 52
5
  7.5.1 Levels of complement components and immunoglobulins 52
  7.5.2 C4A and C4B typing  52
  7.5.3 GAS typing and binding of C regulators 53
  7.5.4 Detection of rhinoviruses 54
 7.6 Statistical analyses 55
8 RESULTS   57
 8.1 Clinical and laboratory findings in adult patients 
  with sinonasal diseases 57
   8.1.1 Overall clinical observations in adult patient groups  57
   8.1.2 Sex differences in respiratory and mucosal          
    infections of sinonasal operation patients 60
   8.1.3 Complement C3 and C4 and CH50 levels 
    in rhinosinusitis patients  61
   8.1.4 Plasma immunoglobulin levels in rhinosinusitis patients 62
   8.1.5 Numbers of functional C4A and C4B genes 
    in rhinosinusitis patients 65
 8.2 Clinical and laboratory findings in pediatric patients 
  with tonsillar diseases  68
  8.2.1 Clinical observations in pediatric patients 68
  8.2.2 Allergic diseases and previous adenoidectomy 
   in tonsillectomy patients 70
  8.2.3 Tonsillar streptococci and binding of complement 
   regulators FH and C4BP 74
  8.2.4 Human rhinoviruses in pediatric tonsillar disease 76
9 DISCUSSION   78
 9.1 Sinonasal diseases in adults 78
  9.1.1 Sexual dimorphism 78
  9.1.2 Complement activation 79
  9.1.3 Complement C4 deficiencies 79
  9.1.4 Immunoglobulin levels 81
  9.1.5 Allergic diseases 82
 9.2 Pediatric tonsillar diseases 83
  9.2.1 Respiratory infections, adenoidectomy and allergy 83
  9.2.2 Complement evasion by GAS in tonsils 84
  9.2.3 Rhinoviruses in tonsils 85
 9.3 General discussion: limitations and findings of special interest 86
10 CONCLUSIONS  90
11 SUMMARY  91
12 TIIVISTELMÄ (FINNISH SUMMARY) 92
13 ACKNOWLEDGEMENTS 93
14 REFERENCES  96
15 APPENDICES  116
16 ORIGINAL PUBLICATIONS 123
6
1 ABSTRACT
Rhinosinusitis in adults and tonsillitis in children are among the most 
common respiratory ailments and cause significant morbidity and ex-
penses. However, the predisposing immunological factors for these are 
largely unknown. The aim of this thesis was to study innate and adaptive 
immune disorders and properties of causative microbes in common up-
per respiratory diseases.
In the first two studies, different patient groups with adult rhinosinusi-
tis (acute, severe chronic, and patients coming to sinonasal operations 
because of recurrent or chronic disease with or without polyposis) were 
studied. These groups were compared with each other and against con-
trol groups. Female patients were more prone to acute and recurrent 
rhinosinusitis as well as to other mucosal infections than male patients. 
Male patients, instead, had more sinonasal polyposis and chronic rhi-
nosinusitis. Female patients with rhinosinusitis had more total and par-
tial deficiencies of complement factor C4B genes than female controls 
or male patients. In concordance with this, increased serum levels of the 
C4 protein were seen in male patients scheduled for sinonasal operation. 
Complement system was upregulated in acute rhinosinusitis in female 
and male patients. Compared with controls, the levels of immunoglobu-
lins IgG1 and IgG3 were lower and those of IgA and IgG2 higher in sino-
nasal operation patients.
In the third study, pediatric patients coming to tonsillectomy were stud-
ied. Children with various indications to operate were compared with 
each other and with age-matched unselected controls. There was an age-
dependent difference in the prevalence of allergic diseases and sensitiza-
tion to respiratory allergens between girls and boys. If a child had had 
recurrent infections earlier and had been operated for adenoidectomy, 
allergy and asthma were more common.
 
In the fourth study, group A streptococci from removed tonsillar tissue 
and blood from septicaemia patients were compared for their ability to 
bind the complement regulators C4BP and FH. It was found that there 
was no difference in the C4BP or FH binding ability between the virulent 
and less virulent strains suggesting that other factors may be more im-
portant for the streptococcal virulence. 
As reported in our last study, rhinoviruses could also, for the first time, be 
detected from tonsillar tissue.
ABSTRACT
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In summary, this study suggests that the development of sinonasal dis-
eases is multifactorial. The underlying factors include predisposing im-
munological alterations that often are subtle in nature, distinct charac-
teristics, like sex, of the patients as well as microbes that have adapted to 
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3 ABBREVIATIONS
ADCC   antibody-dependent cell-mediated cytotoxicity
AOM   acute otitis media
AP   alternative pathway of complement
APC   antigen-presenting cell
ARS   acute/intermittent (presumed bacterial) rhinosinusitis
ASA  aspirin (acetylsalicylic acid)
BCR  B-cell receptor
C   complement 
C4BP   C4b-binding protein
CD  cluster of differentiation
CH50   complement classical pathway hemolytic activity
CP   classical pathway of complement
CRS   chronic rhinosinusitis 
CRSsNP  chronic rhinosinusitis without nasal polyposis
CRSwNP  chronic rhinosinusitis with nasal polyposis
CT  computed tomography
CVID   common variable immunodeficiency
DAF  decay accelerating factor
EPOS  European Position paper on Rhinosinusitis and Nasal Polyps
FH  complement factor H
FcR   Fc receptor
GAS  group A streptococcus, Streptococcus pyogenes
GBS  group B streptococcus, Streptococcus agalactiae
GCS  group C streptococcus
GGS   group G streptococcus 
HLA   human leukocyte antigen
HEV  human enterovirus
HRV  human rhinovirus
ICAM-1 intracellular adhesion molecule 1
IFNγ   interferon gamma
Ig  immunoglobulin
IL  interleukin
ISH  in-situ hybrization
iTreg   inducible T-regulatory lymphocyte
LP   lectin pathway of complement
LRT   lower respiratory tract 
MAC  membrane attack complex
MBL  mannose binding lectin
MHC  major histocompatibility complex
NK   natural killer 
NSAID  non-steroidal anti-inflammatory drug
NP  nasal polyposis
NPO  nasal polyposis only
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NTHI  non-typeable Haemophilus influenzae
OME   otitis media with effusion
PAMP   pathogen-associated molecular pattern
PRR  pattern recognition receptor
PCR   polymerase chain reaction
R  rhinosinusitis
RNA  ribonucleic acid
RT-PCR real-time polymerase chain reaction
RRS  recurrent rhinosinusitis  
sIgA   secretory IgA 
sCRS  severe chronic rhinosinusitis
SNO  sinonasal operation 
Th   T-helper lymphocyte
TLR   Toll-like receptor
TNF  tumor necrosis factor
URT  upper respiratory tract




Upper respiratory tract (URT) diseases are among the most common 
ailments in humans. Little is known yet about possible immunological 
predisposing factors. URT diseases commonly involve inflammation and 
are sometimes caused by infectious agents. For reasons that only recently 
have begun to unravel some individuals have an increased susceptibility 
to these diseases. 
All living plants and animals have their own ways to recognize and react 
to harmless and harmful organisms and substances. These mechanisms 
can be unique or shared by other species, and they can be even used by 
intruders to inflict damage to the host. Vertebrates have developed a so-
phisticated immune defense system to protect themselves from microbial 
attack.
 
Innate immunity provides a strong barrier to protect us from attacks 
by pathogens. However, only a limited number of deficiencies of innate 
immunity have been found to make an individual vulnerable to infec-
tions. Complement is a very powerful effector mechanism of both innate 
and adaptive immunity. Totally defective complement pathway function 
poses a serious risk for infections. Due to its three-pathway organization 
partial defects of one pathway can be, to an extent, compensated by the 
remaining other pathways.
C4 is a key protein of the classical and lectin pathways. Partial deficien-
cies in this most polymorphic protein of the complement system are 
common. Preliminary data suggest that even partial deficiencies of C4, 
together with immunoglobulin deficiencies, may predispose to severe 
rhinosinusitis. However, it is not known how partial deficiencies of C4 or 
immunoglobulins associate with less severe forms of rhinosinusitis. 
In vertebrates, females are often more immunocompetent than males. 
Females and males have varied susceptibility to several infections and 
autoimmune diseases. These differences are not solely explained by ana-
tomical differences or by rare X-linked primary immunodeficiencies 
found exclusively in males. An individual’s sex is thus the most easily 
recognized phenotypic factor that may associate with intrinsic differenc-
es in immune responses. In clinical otorhinolaryngological practice, for 
unknown reasons, a relative excess of females coming to sinonasal opera-
tions is commonly noted.
In sinonasal disease refractory to anti-inflammatory and/or antimi-
crobial treatment, the only remaining therapeutic option is surgery. 
Unfortunately surgery does not always provide satisfactory results. If 
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the immunological background remains unrecognized we cannot direct 
treatment to the cause of the problem. Discovery of new risk factors for 
rhinosinusitis could potentially lead to the development of new forms of 
therapy and further help in the avoidance of unnecessary surgery.
Tonsillar tissues form the ring of lymphoid organs surrounding the up-
per respiratory and alimentary tract (Waldeyer’s ring). This mucosal lym-
phoid tissue takes part in presenting foreign antigens to the adaptive im-
munity. Despite the fact that operative removal of the adenoid or tonsils 
are among the most common operations to pediatric patients, many open 
questions remain. There are contradictory reports about adenoidectomy 
as a predisposing factor for allergy later in life. Rhinovirus, one of the 
most common agents causing pharyngitis and common cold, has been 
recognized as an important precipitator of asthma exacerbations. It has 
been detected in all other parts of the respiratory tract, but not in tonsils. 
Group A streptococci are considered to be the most important pathogens 
in acute tonsillitis but they are also found in healthy tonsils. Is the reason 
for this survival an ability to escape local immune attack, including that 
by the complement system?
The purpose of this study was to explore selected immunological features 
of the host and properties of pathogens and study whether they affect the 
susceptibility to common URT diseases leading to operations.
INTRODUCTION
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5 REVIEW OF THE LITERATURE 
5.1 Immunity in the upper respiratory tract
Mucosal immunity in sinonasal diseases is incompletely understood 
(Ramanathan et al. 2007).  In chronic rhinosinusitis (CRS) the effec-
tors and mediators of adaptive immunity have been studied widely, but 
knowledge concerning innate immunity is still very limited. We know 
that innate immunity mechanisms are responsible for most of pathogen 
recognition, destruction and disposal. Only a limited amount of patho-
gens are capable of penetrating the multiple barriers of innate immunity. 
Sometimes, for example in the tonsillar tissue, this may be allowed for the 
purpose of sampling material to stimulate adaptive immunity responses 
(Nave et al. 2001). 
Differences between innate and adaptive responses are shown in Figure 
1a and clinically relevant defects in these responses in Figure 1b (Fokkens 
et al. 2000). The humoral arm of innate immunity is capable of acting im-
mediately against microbes with potent antimicrobial substances. It also 
triggers the cellular arm of innate immunity for action by opsonization 
of microbes and recruiting phagocytic cells to remove the foreign mate-
rial. Pattern recognition receptors (PRRs) can recognize pathogen-asso-
ciated molecular patterns (PAMPs) and also non-viable host structures 
(Ramanathan et al. 2007). These receptors (toll-like receptors, TLR; man-
nose receptor, ManR; scavenger-receptor, ScaR; CD14, CD36 and Marco) 
on the surfaces of antigen presenting cells (APCs) are capable of captur-
ing and processing microbial structures and inducing inflammation and 
immune reactions. It is important that both exogenous and endogenous, 
potentially harmful, material is rapidly neutralized and then removed 
from the system with effective phagocytosis to allow inflammation to at-
tenuate (Meri 2007). Different pathogen recognition mechanisms of in-
nate immunity can trigger and upregulate adaptive immune responses 
that links these two arms of defense. 
B-lymphocytes are able to recognize microbial polysaccharides directly 
with their surface receptor (B-cell receptor, BCR), but recognition of 
peptides requires T-cell help (Bondada et al. 2005). Antigen presenting 
cells (dendritic cells, macrophages, B-cells) take in microbial and non-
viable host protein structures with their specific receptors and process 
them into peptides that can be presented to naive CD4+ T-lymphocytes 
on class II major histocompatibility complex (MHC II). Presentation oc-
curs in the lamina propria of mucosal surfaces or in the local lymphoid 
structures, in the upper respiratory tract in the Waldeyer’s (tonsillar) 
ring. These lymphocytes can be primed to T helper one (Th1), T helper 
two (Th2), inducible regulatory Tcells (iTreg) or T helper 17 (Th17)-
REVIEW OF THE LITERATURE
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lymphocytes depending on the nature of stimuli and local cytokine en-
vironment. T-lymphocytes induce the proliferation of antigen-specific 
B-lymphocytes and production of immunoglobulins (Igs) by plasma cells 
that can then undergo clonal multiplication (Janeway 2005; Martinez et 
al. 2008).
Immunoglobulins, the main humoral effectors of adaptive immunity 
have an interesting dual role on innate immunity. They activate the classi-
cal pathway of complement to induce lysis of a recognized microbe.  They 
are also able to bind and promote elimination of both large fragments 
C3b and C4b and complement-derived anaphylatoxins C3a and C5a and 
limit potentially harmful inflammation. In this way adaptive immunity 
can regulate the activity of the innate immunity (Basta 2008).
REVIEW OF THE LITERATURE
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Figure 1a. The different sections and effector mechanisms of immunity. 
 
Figure 1b. Clinically relevant defects in different sections of immunity.
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In upper airways, the mechanisms of innate immunity provide us the 
primary defense against pathogens. Several independent and overlap-
ping innate mechanisms make their evasion difficult. Nonspecific and 
microbe-specific innate immune defense mechanisms in the sinonasal 
cavity and clinically relevant defects in these systems associated with rhi-
nosinusitis are listed in Table 1 (Fokkens et al. 2000). Even in the case of 
passing this first barrier, information on the identity and the nature of 
the pathogen is passed on to the adaptive immune system for secondary 
response. 
5.2.1. Cellular innate immunity
The cellular part of innate immunity consists of several cell types. 
Neutrophils can phagocytose and destroy opsonized pathogens, espe-
cially extracellular ones. Monocytes, which develop into macrophages, 
are more efficient against intracellular pathogens. Macrophages are im-
portant both in phagocytosing cells and nonviable or foreign material 
and in directing immune responses by the production of cytokines. They 
also act as APCs for adaptive cellular immunity (Godthelp et al. 1996). 
Eosinophilic cells act against large pathogens such as parasites and release 
enzymes and proteins to perforate cell membranes. They are also effector 
cells in allergic inflammation (Prussin et al. 2006). A special type of lym-
phocytes, natural killer cells (NK-cells) can kill pathogens and infected 
host cells with secreted substances and also produce cytokines (interfer-
on-gamma, IFNγ) that enhance adaptive immunity (Janeway 2005).
REVIEW OF THE LITERATURE
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Table 1. Upper airway innate defense mechanisms and their defects in 
chronic rhinosinusitis.  
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Table 1. r airway innate d fense mechanisms and their defects in chronic 
rhinosinusitis.   
FACTOR MECHANISMS EFFECT DEFECT IN CRS 
BARRIERS 
   
Ciliary function Mucociliary transport 
Increased flow in infection 
and due to airborne irritants 
Eliminating pathogens by 
transport to alimentary tract 
Trauma (surgery etc.) 
Viral infection 
Radiotherapy 
Primary ciliary dyskinesia (PCD) 












Mucus High molecular weight 
glycoproteins 
Salt consentration 
Physical barrier protecting 
epithelial cells 








   
Lysozyme Destroys peptidoglycan cell 
wall of bacteria 
 
Toxic to fungi 
Needs lactoferrin, ntibody-
complement complexes or 




Lactoferrin Binds iron 




Effective against Candida  
 
Others ß-defensins, secretory 
leukocyte protease inhibitor , 
secreted phospholipase A2, 
cathelicidins, nitric oxide  
 
Inhibit microbial growth 
Direct microbicidal activity 
Recruit phagocytic cells 
Develop adaptive response 
ß-defensin2 decreased in epithelial 
cells in chronic rhinosinusitis with 
nasal polyposis (CRSwNP) 




   
Complement Pathogen opsonization 
Phagocyte activation 
Lysis of bacterial cells 
 
Enhances phagocytosis 
Direct killing of pathogens 
 
Serum amyloid A Opsonization 
 
Bind directly to Gram+ bacteria   
Surfactant proteins 
SP-A and SP-D 
Bind and agglutinate non-





Initiate and enhance immune 
cell ingestions and killing of 
targets 
Decreased SP-A levels in 














Promote phagocytosis  
Toll like Receptors 
(TLR1-9) 
 
Signalling in macrophages, 
dendritic cells, endothelial 
cells and epithelial cells 
 
Induce local primary immune 
defensive mechanisms 
Alert adaptive immune system 
Induce immune tolerance to 
normal flora? 
 
TLR9 decreased in CRSwNP 
(Lane et al. 2006) 
a
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5.2.2 Complement activation and regulation
Complement (C) proteins form the major effector mechanism of innate 
humoral immunity. The C system consists of about 35 components form-
ing a three-pathway system, where proteins are activated in a cascade 
fashion with potent amplification steps and effective regulatory factors 
(Figure 2). The three pathways enable a very large repertoire of triggers 
and functions for C. Primary roles of C proteins are to activate the in-
flammatory response, opsonize microbial pathogens and nonviable host 
components (cellular debris, apoptotic cells etc) for killing and phagocy-
tosis and to lyse susceptible organisms. Complement is also a very im-
portant link between innate and adaptive responses through receptors in 
B-lymphocytes and APCs. Complement activation is normally targeted 
and very tightly regulated because its powerful destructive capacity may 
also damage the host. 
Through a complex series of protease-activated cleavages of C proteins 
and their interactions the three pathways unite for a terminal pathway 
(Figure 2). The resulting membrane attack complex (MAC) is capable of 
forming transmembrane pores to promote complement-mediated lysis 
of cells. 
Complement activation is tightly regulated by membrane bound and 
soluble regulators at three main levels (Figure 2). First, the initiation step 
of the classical pathway is regulated by C1-esterase inhibitor (C1-INH), 
which is a serine proteinase inhibitor (serpin) (Du Clos 2008). Secondly, 
the C3 and C5 convertases are regulated by C3b inactivator (factor I), 
soluble regulatory proteins C4b binding protein (C4BP) and factor H 
(FH) and by the membrane bound regulatory proteins CD55 (decay ac-
celerating factor, DAF), CD46 (membrane cofactor protein, MCP) and 
CD35 (complement receptor 1, CR1) (Hourcade et al. 1989; Giannakis et 
al. 2003). The newest membrane regulatory proteins are C2 receptor in-
hibitor trispanning (CRIT), complement receptor of the immunoglobu-
lin superfamily (CRIg) and the CUB and sushi multiple domains protein 
(CSMD1) (Inal et al. 2002; Helmy et al. 2006; Kraus et al. 2006). Properdin 
stabilizes the alternative pathway C3 and C5 convertases increasing their 
activity (Liszewski et al. 1996).  Thirdly, the MAC formation is controlled 
by soluble MAC inhibitors S-protein and clusterin and by the membrane 
bound inhibitor CD59 (protectin) (Davies et al. 1993; Tschopp et al. 1994; 
Schvartz et al. 1999).
REVIEW OF THE LITERATURE
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Figure 2. The complement system. The parts included in this study encircled 
and bolded.
Special thanks to Matti Laine for comprehensive illustration. (Modified 
from Matti Laine)
5.2.3. Complement function and deficiencies
The classical (CP) pathway of complement is activated by IgM- or IgG-
containing immune complexes, by some PRR molecules (CRP and serum 
amyloid P-ligand complexes) and phospholipids in ischemic and apop-
totic cells (Figure 2). The lectin pathway (LP) uses CP components, but 
is activated by mannose binding lectin (MBL) and by ficolins recogniz-
ing repeating simple carbohydrate patterns in microorganisms, apoptotic 
cells and occasionally glycosylated IgA or IgM bound to antigens. The 
alternative pathway (AP) can be activated by bacterial components (li-
popolysaccharide (LPS), teichoic acids), fungal cell wall polysaccharides, 
virus-infected cells (measles, influenza, Epstein-Barr-virus), IgA contain-
ing immune complexes, C3 nephritic factor (C3NeF), cobra venom fac-
tor, some tumor cell lines and deoxygenated sickle cells. The AP can also 
be initiated through CP activation. It is also capable of autoactivation in 
the absence of inhibitory signals. A special feature of the AP is amplifica-
tion of its own activation to further enhance opsonization and to pro-
mote activation of the terminal pathway. 
REVIEW OF THE LITERATURE
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In host defense, C-dependent opsonization is most important against 
infections by encapsulated extracellular bacteria like Hemophilus in-
fluenzae and Streptococcus pneumoniae. Increased susceptibility to in-
fections caused by these bacteria is seen in individuals with deficient 
antibody production, neutrophil function or lack of C3. MBL variants 
are also associated with pyogenic infections in young children (Turner 
1998). Gram-negative bacteria are susceptible to complement-dependent 
lysis. Individuals with deficiency of C3, any of the MAC components or 
properdin have an increased incidence of disseminated neisserial infec-
tions, notably of meningococcal meningitis (Densen 1991).
 
Complement promotes inflammation by anaphylatoxins C5a and C3a, 
which are cleaved from C5 and C3 during complement activation. These 
act also as chemotactic factors for neutrophils and macrophages. C5a 
also prevents apoptosis of neutrophils by prolonging their survival and 
promoting accumulation to inflammation site. They also affect the T-cell 
responses to antigen through their effects on lymphocytes and APC ac-
tivity.
Damaged tissue compounds and apoptotic cells are recognized by mul-
tiple receptors and opsonins and can activate complement through sev-
eral pathways. Timely clearance of nonviable material is needed to avoid 
the development of autoimmunity. Failure of complement-dependent 
opsonization due to early CP deficiencies (C1, C4 and C2) can lead to 
accumulation of apoptotic cells and persistence of autoantigens, charac-
teristic of systemic lupus erythematosus (SLE) (Meri 2007). Factor D and 
properdin deficiencies result in an inability to activate the AP and to an 
increased susceptibility to neisserial infections. FH and FI deficiencies 
and the presence of C3NeF can lead to a severe acquired C3 deficiency 
and lack of regulation of fluid phase C3 convertases. As a consequence 
infections and membranoproliferative glomerulonephritis type II may 
develop. Serum carboxypeptidase N deficiency leads to a failure to con-
trol C3a, C5a and bradykinin and results in recurrent angioedema and 
urticaria. Recurrent angioedema (HAE) is a result of loss of regulation of 
C1s, C1r and kallikrein due to C1-INH deficiency (Nzeako et al. 2001). 
FH, FI and CD46 mutations can result in a lack of regulation of mem-
brane C3 convertases and atypical hemolytic uremic syndrome (aHUS). 
Furthermore, polymorphisms in FH predispose to age-related macular 
degeneration (AMD) (Edwards et al. 2005; Haines et al. 2005; Klein et al. 
2005). Lack of DAF and CD59 leads to a failure to regulate complement 
activation on autologous blood cells and results in paroxysmal nocturnal 
hemoglobinuria (PNH) (Meri 2007).
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5.2.4 Complement evasion by pathogens
Innate immunity forms the major barrier protecting the host from poten-
tially harmful exogenous and endogenous factors. Survival strategies of 
respiratory pathogens in the respiratory tract must include effective eva-
sion mechanisms of different components of immunity. Evasion of com-
plement activation is important for the survival of pathogens in tissues. 
One sign of the importance of complement in the rejection of pathogens 
is the fact that many of them have developed several strategies to evade 
complement activation (Table 2) (Du Clos 2008). The acquisition of sol-
uble host complement regulatory factors is a clever way to camouflage 
from opsonization and phagocytosis. C4BP and FH are important regu-
lators of the complement classical and alternative pathway, respectively. 
FH binds to C3b and accelerates the dissociation of the AP C3 convertase 
C3bBb. It is also a cofactor for factor I the cleavage of C3b (Blom et al. 
2003). C4BP binds to C4b, and acts as a cofactor of factor I in the cleav-
age of C4b. It also accelerates the decay of the CP C3 convertase of C4b2a 
(Du Clos 2008). 
REVIEW OF THE LITERATURE
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Table 2. Complement evasion strategies by pathogens. Studied mechanism 
of S. pyogenes in bold.   
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Table 2. Complement evasion strategies by pathogens. Studied mechanism of S. 










Block MAC action Salmonella 
Block AP activity 




Neisseria meningitidis group B 
Limit access of C3 





Bind FH, C4BP to 
limit C activation 
S. pneumoniae (Hic) 




Use DAF, CD46 
for attachment to 
cells 






Use C receptors 
(CR3) for entry 
 









regulators for entry 
Epstein-Barr virus (CR2) 
HIV (CR3) 
Measles virus, adenovirus, herpesvirus 6 
(MCP) 







Trypanosoma (DAF-like protein) 
 
Take up C 
regulatory proteins 
 
Schistosoma (DAF and CD59) 
Parasites 
Use C receptor for 
entry 
 
Leishmania (CR1, CR3) 
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5.2.4.1 Group A streptococci and immune evasion
The group A streptococci (Streptococcus pyogenes, GAS) are extracellular 
gram-positive pathogens that cause a variety of infections. These range 
from mostly mild and common diseases (pharyngotonsillitis, impetigo, 
cellulitis, erysipelas, scarlet fever) to severe, life-threatening (up to 10% 
mortality) invasive infections like necrotizing fasciitis, streptococcal toxic 
shock syndrome or symptomatic bacteremia (Cunningham 2000). Even 
the mild and common superficial infections may cause remarkable mor-
bidity as they sometimes lead to post-infectious immunological compli-
cations such as poststreptococcal glomerulonephritis, rheumatic fever 
and reactive arthritis (Cunningham 2000). Several potential virulence 
factors for GAS have been found. They include hyaluronic acid capsule, 
M-protein, C5a peptidase and serum opacity factor. The relevance of 
these factors to clinical disease has not, however, been clearly established 
(Jarva et al. 2003).
An important factor to GAS virulence is the fibrillar surface M-protein. It 
is a dimeric protein with a coiled structure. Its multiple functions include 
antiphagocytic activity, autoaggregation of bacterial cells, adherence to 
host tissues and intracellular invasion (Bisno et al. 2003). It has a distally 
projecting N-terminus containing a hypervariable region that has been 
used to define more than 100 M-serotypes (Facklam et al. 2002). GAS 
mutant strains lacking M-protein are readily phagocytosed, after being 
opsonized mainly by components of the classical pathway of C (Fischetti 
1989; Bisno et al. 2003; Carlsson et al. 2003). The antiphagocytic property 
of GAS strains is usually serotype-specific and can only be transferred 
to types sharing a genetically homologous background (Kotarsky et al. 
2000). Small epidemics caused by specific M-protein expressing strains 
have been described (O’Brien et al. 2002; Beres et al. 2004). Two of the 
most common serotypes causing invasive and toxic streptococcal infec-
tions are considered to be M1 and M3 (Colman et al. 1993; Cunningham 
2000). GAS has several mechanisms to avoid host innate and adaptive 
responses and these are listed in Table 3 (Kwinn et al. 2007).
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Table 3. Immune evasion mechanisms of Group A streptococci. Studied 
mechanism in bold.
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Table 3. Immune evasion mechanisms of Group A streptococci. Mechanisms 









Cleaves the complement-derived 
chemoattractant peptide C5a 
 




DNAses Prevent capture in DNA-based 




Mimics common human matrix 
component 
Blocks opsonins from bacterial surface 
 
M-, M-like proteins 
and Sfb1 
Recruit host matrix proteins 
(fibronectin, fibrinogen, collagen) 
to form protective coating 
 
M-protein Binds complement regulators C4BP 
and FH limiting C3b deposition 
 
Inhibition of complement 
function  
SIC Interferes with formation of MAC 
 
M-protein, Sfb1 Bind immunoglobulin nonopsonically 
via Fc domain 
 
Antibody function inhibition 
Cysteine protease SpeB Degrades immunoglobulins 
 
EndoS Hydrolyses IgG glycans involved in 
Fcgamma recognition 
 
Mac-1, Mac-2 Bind to neutrophil Fc receptors, inhibit 
recognition of IgG on bacterial surface 
 
Phagocytosis impairment 
SIC Impairs actin cytoskeletal 




Streptolysin S and O 
Cytotoxic to neutrophils and 
macrophages 
 
Phagocyte lysis and promotion 
of apoptosis  
Whole cells Induce accelerated apoptosis program 
in human neutrophils 
 
Resistance to phagocyte killing SIC, SpeB proteolysis 
and D-alanylation of 
lipoteichoic acid 
 
Interfere with host cationic 
antimicrobial peptide function 
 Whole cells 
 
Can escape the phagosome 




5.2.5 Innate immunity in adenotonsillar tissue 
Pharyngeal, palatine, lingual and tubal tonsils, prominent parts of the 
Waldeyer’s ring are usually small in the newborn, but grow in size during 
the first 1 to 5 years of life. They are immunologically most active be-
tween 4 and 10 years of age, and begin to decrease in size during puberty, 
yet their Ig production is maintained to old age (Wiatrak 1998).
Figure 3. Waldeyer’s tonsillar ring. Tonsillar tissue localization in the upper 
airways.
Tonsillar tissue forms a torus-like formation surrounding upper airways, 
the so-called Waldeyer’s ring (Figure 3). It consists of nasopharyngeal-
associated lymphoid tissue (NALT), which is capable of follicle formation 
(Boyaka et al. 2000; Nave et al. 2001). Waldeyer’s ring is an essential part 
of upper airway microbial defense acting both locally and systemically. In 
this secondary lymphoid tissue weak antigenic signals are eliminated and 
strong antigenic signals start the proliferation of antigen-specific B-cells. 
Tonsillar tissue functions actively in innate immunity and is also capable 
of regulating humoral adaptive immunity (Boyaka et al. 2000).
Adenotonsillar tissue is an important region for the induction of immu-
nological responses. Microbes attach to the epithelial surface of tonsils 
covered by a viscous secretion containing several antimicrobial factors 
of innate immunity. Surface crypts allow the microbes to come into con-
tact with macrophages and dendritic cells through specialized reticular 
epithelium. The adenoid tissue is well organized to T and B-cell areas 
and is capable of antigen uptake, processing, presentation, T/B-cell co-
operation, maturation and differentiation (Boyaka et al. 2000; Nave et al. 
2001).
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Several potentially pathogenic bacteria are harbored in the human na-
sopharynx (S. pneumoniae, non-typeable H. influenzae (NTHI), Neisseria 
meningitidis and Moraxella catarrhalis (Forsgren et al. 1995). With in-
situ DNA/RNA hybridization NTHIs has been demonstrated to reside 
and multiply intracellularly in subepithelial macrophages in the reticular 
crypt epithelium of human adenoid tissue (Forsgren et al. 1994). With 
DNA fingerprinting, NTHIs have been found to cause endogenous re-
infections of acute otitis media after intracellular survival (Samuelson et 
al. 1995). 
5.3 Adaptive immunity
Adaptive immunity functions mainly through antibody action on anti-
gen-carrying pathogenic substances or via T-cells recognizing peptides 
on MHC-molecules. Adaptive immunity is tightly regulated to ensure 
that damage is inflicted only to infective agents and harmful exogenous 
material. In autoimmunity, this control is breached and immune defense 
is activated against endogenous host structures causing damage to self 
(Janeway 2005).
5.3.1 Cellular adaptive immunity
Pathogen contact with APC triggers cellular adaptive immunity. These 
APCs, monocyte-derived Langerhans cells, DCs or macrophages can 
migrate actively between tissues and blood or lymphatic circulation. 
Activation occurs when PAMPs are recognized by PRRs and TLRs on 
the surface of APCs. APCs take in and process antigens into peptides and 
present them to naive CD4+ T-lymphocytes on class II major histocompat-
ibility complex (MHC II) receptors with simultaneous cytokine excretion 
(Janeway 2005). Cytokine levels regulate naive T-cells’ differentiation into 
different effector cells. IL-12 leads to T-helper 1 (Th1), IL-4 to T-helper 
2 (Th2), tumor growth factor-beta (TGF-B) to inducible T-regulatory 
lymphocytes (iTreg), or T-helper 17 (Th17) development (Martinez et al. 
2008). When activated, each T-cell has a different immunological func-
tion. Th1 promote the development of cytotoxic T-cells, natural killer 
cells and IgG-producing lymphocytes leading to antigen presentation and 
cellular immunity. Th2 promote humoral immunity by the development 
and maturation of IgG-, IgA- and IgE-producing B-lymphocytes, eosi-
nophils and mast cells and also promote allergic and asthmatic responses. 
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iTregs lead to lymphocyte homeostasis, immune tolerance and regulation 
of immune responses and Th17 to tissue inflammation and autoimmune 
processes (Martinez et al. 2008; Zhu et al. 2008).
Figure 4. T-helper cell subset differentiation (modified from Martinez 
2008).
 
LPS = lipopolysaccharide, mDC = mature dendritic cell, IL = interleukin (IL-4, IL-12, IL-21, IL-23
etc), Naive = naive CD4+ T-lymphocyte, T-bet = T-box expressed in T cells, LT = lymphotoxin (LTα), 
GATA3 = GATA-binding protein 3, FOXP3 = Forkhead box P3, TGF = tumor growth factor (TGFβ), 
ROR = retinoic-acid-receptor-related orphan reseptor (RORγt, RORα), DR = death receptor (DR3), 
TL1a = TNF-family cytokine, M∅ = monocyte-macrophages, CCL = chemokine ligand (CCL20)
5.3.2 Humoral immunity
The adaptive humoral immune system is based on the ability of Igs to 
recognize and bind antigen through the highly variable V-region and in-
teract with the conserved effector systems through constant C-regions. 
Two identical binding sites allow IgG to bind with a high avidity to anti-
gens with repeating epitopes or to aggregates of antigen (Clark 1997). The 
binding of antibody to antigen may directly inactivate an infectious agent 
by blocking functional sites with receptor binding or enzymatic activity. 
However, most often, the antigen bound antibody interacts with other 
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components of the immune system (Janeway 2005). These interactions 
can lead to activation of complement through the classical pathway or 
to binding to receptors of various cell types. Both processes assist the 
opsonization of antigen, trigger inflammation and enhance an immune 
response against the infectious agent (Wingren et al. 2005).
5.3.2.1 Immunoglobulins
 
Immunoglobulins are glycoproteins with antibody function and 
found in all vertebrates. They exist as membrane bound receptors in 
B-lymphocytes, which after maturing to plasma cells secreted them as 
proteins. These constitute up to 10-20% of plasma proteins in mammals. 
Igs are mostly formed from two “heavy” and two “light” chains mak-
ing symmetrical structural subunits with two identical antigen-binding 
sites (Wingren et al. 2005). The N-terminal domain, called variable or 
V-domain (Fab), gives rise to its specificity for its antigen and further 
to differences in antibody-binding affinity caused by somatic gene rear-
rangements and mutations (Janeway 2005). After pathogen recognition, 
during antibody response, the antigen specific B-cell clone secretes its 
B-cell receptor V-domain attached to a constant C-region domain (Fc). 
The elected C-domain defines the isotype  (“class”) of the antibody and 
further allows it to perform different effector functions. Different classes 
of immune effector cells carry different Fc receptors (FcR) and thus dif-
ferent antibody (sub)classes activate different effector cells (Clark 1997) .
In mammalians Igs exist in 5 classes: IgG, IgA, IgM, IgD and IgE. In hu-
mans, IgA is divided into two subclasses and IgG into four subclasses. 
Each B-cell produces an antibody with a single type of heavy chain as-
sociated with a single type of light chain (Wingren et al. 2005). IgG is the 
main mammalian Ig class. In humans, the four IgG subclasses show over 
90% homology in the C region domains probably as a result of recent 
duplications in evolution. The half-life of IgG is much longer (3-4 weeks) 
as compared to the other Ig classes (IgA, IgM 3-7 days) and is inversely 
related to the total concentration of IgG in plasma (Clark 1997; Janeway 
2005). 
5.3.2.2 IgM, IgA and IgD
In addition to the cell bound IgM in the BCR, IgM is mostly found in 
the intravascular pool. It is the first antibody produced in the primary 
response and has a multimeric, most often pentameric structure. IgM is 
a potent binder of antigens and a strong C activator. It acts as an opsonin 
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and aids in the clearance of apoptotic cells (Ochs 2008).  Natural antibod-
ies are of IgM class. Constantly low IgM is associated with autoimmunity, 
hypersensitivity and with recurrent infections (Goldstein et al. 2006). 
There are two forms of IgA, dimeric secretory IgA (sIgA) and monomeric 
serum IgA. Secretory IgA is produced locally in the mucosal surfaces, 
mainly in the gut associated lymphoid tissue (GALT). It serves as the first 
line of humoral defense and is capable of neutralizing viruses and tox-
ins, opsonizing pathogens and blocking bacterial entry across mucosal 
surfaces (Woof et al. 2006). Serum IgA has a short half-life. Up to 60% of 
daily Ig production in humans is of IgA type. However, more than half 
of produced IgA is selectively transported to external secretions as sIgA. 
IgA has two subclasses IgA1 and IgA2.  In serum IgA1/IgA2 ratio is 9:1 
but in secretions this ratio is much more even. IgA is a poor opsonizer 
and complement activator. Antigen binding to IgA fails to initiate various 
inflammatory processes. On the contrary, to protect mucosal surfaces, it 
may inhibit excessive complement activation by complement fixing Igs. 
The function of serum IgA is poorly known, but it also may have anti-
inflammatory functions (Jacob et al. 2008). IgA deficiency is the most 
common primary immunodeficiency, but most of its carriers are asymp-
tomatic or suffer from only minor, noninvasive infections. In Finnish 
blood donors, its incidence was 2.5/1000 (Koistinen 1975). IgA deficiency 
has been associated with frequent mucosal infections, atopy, and certain 
immune diseases, like the celiac disease (Koistinen 1975; Cunningham-
Rundles 2001; Woof et al. 2006; Latiff et al. 2007). Predisposing genes to 
IgA deficiency have recently been found (Sekine et al. 2007; Haimila et 
al. 2008).
IgD makes only 0.25% of the Ig population and its serum levels are low. 
IgD is mainly found as a membrane bound BCR and its precise function 
is unknown (Wingren et al. 2005).
5.3.2.3 IgG and IgG subclasses  
IgG is the most abundant circulating antibody class; it composes 70-75% 
of the total serum Ig. It is evenly distributed to the intra- and extravascular 
pools. Most anti-protein antibodies are of IgG1 and IgG3-type, whereas 
IgG2 and IgG1 are effective against pathogens with polysaccharide anti-
gens. Ig subclasses IgG1-4 differ from each other in their effector func-
tions (Pan et al. 2000). IgG1 is most effective in activating complement 
and in triggering cell-mediated cytotoxicity (antibody-dependent cell-
mediated cytotoxicity, ADCC). IgG3 does the same, but with somewhat 
weaker efficiency than IgG1. IgG1 function is more effective when anti-
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gen concentrations are higher; IgG3 works relatively better at low antigen 
concentrations. Due to the shorter half-life of IgG3, IgG1 levels in plasma 
are 10-20 times higher than IgG3 levels though more IgG3 is produced. 
IgG1 and IgG3 both activate the CP (Janeway 2005). The production of 
IgG1 and IgG3 is thought to be enhanced by Th1-dominant inflamma-
tory responses. IgG1 and IgG3 are capable of all antibody mediated effec-
tor functions (Pan et al. 2000).
IgG2 and IgG4 appear during the secondary immune response and their 
main functions is to neutralize extracellular antigens. IgG2 is important 
in anti-polysaccharide antibody responses. It is able to trigger comple-
ment lysis only at very high concentrations and does not trigger ADCC. 
IgG4 does not activate C nor induce ADCC under any conditions. IgG2 
production is enhanced by Th2 dominant inflammatory responses, and it 
is the most abundant subclass to react with carbohydrate antigens. IgG4 
production is enhanced in response to prolonged exposure to mucosal 
antigens causing a Th2 type response, such as during simultaneous expo-
sure to multiple allergens or helminth infection (Clark 1997). 
5.3.2.4. IgG subclass deficiencies
Individuals with low IgG subclass levels are common and they are fre-
quently asymptomatic (Maguire et al. 2002). In children, there is a 3:1 
male to female preponderance in low subclass levels. Boys have more fre-
quently low IgG1 levels (Lacombe et al. 1997). Low IgG2 and abnormal 
vaccine responses are more frequent in children. After puberty, low IgG1 
and IgG3 levels are seen more often, especially in females. Selective IgG1 
deficiency without low levels of other subclasses is associated with mostly 
moderate upper respiratory tract infections and sinusitis caused by S. 
pneumoniae or H. influenzae. Only 12% of symptomatic IgG1 deficient 
individuals get severe infections (Lacombe et al. 1997). Severely symp-
tomatic patients with low IgG1 (and thus almost always low IgG) levels 
and impaired responses to polysaccharide antigens are diagnosed to have 
common variable immunodeficiency (CVID) or specific antibody defi-
ciency (SAD). These patients are candidates for subcutaneous or intrave-
nous Ig substitution therapy, if prophylactic antibiotics are not sufficient 
or serious end-organ damage is found (Buckley 2002; Maguire et al. 2002; 
Bonilla et al. 2005; Orange et al. 2006; Provan et al. 2008).
The clinical significance of low IgG3 level is controversial. It is associated 
with frequent, but mild URTI, bronchitis, bronchopneumonia, bronchial 
asthma, and erysipelas episodes and with recurrent herpes simplex vi-
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rus infections (Oxelius et al. 1986; Morgan et al. 1988; Aucouturier et 
al. 1994; Seppänen et al. 2006). These patients rarely have impaired re-
sponses to vaccines. 
Individuals with selectively low IgG2 levels are also usually asymptomatic. 
In children, IgG2 deficiency is associated with recurrent sinopulmonary 
infections caused by S. pneumoniae, H. influenzae and M. catarrhalis. The 
association is strong only if associated with an impaired vaccination re-
sponse (Buckley 2002; Bonilla et al. 2005). Symptomatic selective IgG2 
or IgA deficiencies in childhood may progress to CVID, but Ig levels and 
vaccination responses may also normalize and patients become asympto-
matic (Bonilla et al. 2005; Orange et al. 2006).
A combination of low levels of IgG1 and IgG3 is frequently seen in pa-
tients with nonatopic or atopic bronchial asthma with sinopulmonary 
symptoms (Lacombe et al. 1997). This phenomenon seems to be associ-
ated with Th2 dominant immune responses (Avery et al. 2008). IgA defi-
ciency is a predisposing factor to atopic and certain immune diseases, like 
celiac disease (Haimila et al. 2008). Sinopulmonary symptoms caused by 
atopic diseases together with recurrent sinopulmonary infections associ-
ated with IgG1, IgG3 and IgA deficiencies in the same patient constitute 
a diagnostic dilemma (Lacombe et al. 1997; Cunningham-Rundles 2001; 
Buckley 2002; Wood et al. 2007).
5.3.2.5 IgE and allergy 
IgE mainly exists bound to its receptors in various cells and is present 
in only very low quantities in serum. IgE makes only about 0.002% of 
the total Ig pool and 50% of it is found intravascularly with a half-life of 
1-5 days. IgE is involved in parasite and allergen-specific Th2-dominant 
responses (Figure 4) (Galli et al. 2008). The main actions of IgE are medi-
ated through basophils, mast cells and eosinophils, where cross-linking 
of IgE FcεRI- receptors causes the release of inflammatory mediators, 
proteases and cytokines [histamin, leukotrienes and platelet activating 
factor (PAF)] from the secretory granules (Prussin et al. 2006). In addi-
tion to this immediate IgE-mediated hypersensitivity reaction, mast cell 
activation contributes to the delayed hypersensitivity reaction by releas-
ing histamine, lipid mediators and cytokines. Eosinophil activation also 
contributes to the allergic late reaction by releasing basic proteins, leuko-
trienes and PAF. Besides allergy, there are several diseases causing high 
levels of IgE: parasitic and some viral infections, hematological malig-
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nancies, autoimmune disorders, hyper-IgE syndromes and several forms 
of combined immunodeficiencies (Prussin et al. 2006; Galli et al. 2008; 
Pien et al. 2008).
IgE does not activate complement. Interestingly, activation of comple-
ment receptors C3aR and C5aR by anaphylatoxins C3a and C5a acts syn-
ergistically with IgE-mediated responses (Prussin et al. 2006).
 
Hypersensitivity causes objectively reproducible symptoms or signs, ini-
tiated by exposure to a defined stimulus at a dose tolerated by normal 
subjects. Atopy is a personal or familial tendency to produce IgE antibod-
ies in response to low doses of allergens, usually proteins, and to develop 
typical symptoms such as asthma, rhinoconjunctivitis, or eczema/der-
matitis.  Allergy is a hypersensitivity reaction initiated by immunologic 
mechanisms (Johansson et al. 2001).
Allergens are usually proteins, or rarely inorganic substances that first 
have to bind to a host protein to form a hapten before they become al-
lergens (Johansson et al. 2001). Allergens can cause hypersensitivity reac-
tions in several ways. If an allergen binds to IgE and induces histamine 
release from effector cells, it is considered a true allergen. Most respira-
tory (pollens, dusts) and some of the food allergens (e.g. egg, milk) be-
long to this group. In these cases, skin prick testing and tests to detect 
specific IgE against allergens are positive. If the allergen does not bind 
to IgE, but is capable of inducing histamine release, it is considered to 
be a nonspecific histamine liberator. Analgesic morphine or some fruits 
(kiwi) belong to this group. If the allergen does not bind IgE and does 
not release histamine it is considered to function through cell-mediated 
or other mechanisms. Metallic nickel and some artificial scents belong to 
this group; these can be assessed with epicutaneous testing. Finally, al-
lergic symptoms can be caused by a substance not binding IgE, but itself 
containing histamine or other biogenic amines (Jansen et al. 2003). The 
meat of a marine predatory fish species (e.g. tuna), allowed to warm up 
after catching belong to this group. Some wines and cheeses may also 
contain biogenic amines (Budde et al. 2003).
The clinical diagnosis of allergy is confirmed when either allergen-specific 
IgE is found from the serum or when skin prick testing (SPT) is positive, 
in conjunction with compatible symptoms (allergic rhinoconjunctivitis, 
bronchial asthma or cutaneous or gastrointestinal allergic symptoms). 
There are, however, exceptions making the diagnosis more challenging. 
Specific IgE can be found and/or SPT can be positive in atopic patients 
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even without allergic symptoms.  Conversely, in patients who have devel-
oped clear seasonal allergic symptoms both specific IgE and SPT testing 
may be falsely negative due to only local IgE production and/or IL-10 
mediated suppression of IgE production (Heaton et al. 2005). Also al-
lergen extract quality, seasonal variations in IgE synthesis, patient's age 
and medication may influence the reliability of allergy testing (Bousquet 
et al. 2008). 
The nose is an important route for sensitization to respiratory allergens 
(Vinke et al. 1999). CD1a+ Langerhans cells (APCs) are found in the nasal 
mucosa. These are capable of presenting allergens to T-cells in the lamina 
propria and lymphoid tissue (Fokkens et al. 1992). Most of antigen pres-
entation occurs in the regional draining lymphoid tissue composed by 
the Waldeyer’s ring (Winther et al. 1994).  In the adenoid tissue, CD1a-
positive cells are found in larger numbers in children with allergic disease 
than in non-allergic children. A similar increase in APCs has been seen 
in nasal mucosa of allergic patients after allergic challenge. Larger num-
bers of eosinophils, important effector cells in allergic reactions, have also 
been found in the adenoid tissue of allergic children when compared to 
controls. These cells that normally are seen in the mucosal lining of aller-
gic “shock organs” (airways, gut) are rapidly recruited and activated after 
allergen stimulation (Godthelp et al. 1996).
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5.4 Upper airway diseases
5.4.1 Sinonasal disease definitions
       
Rhinosinusitis (R) is the common term for concurrent rhinitis and sinusi-
tis. This disorder is common in both adults and in children. The defini-
tion of rhinosinusitis has changed during the last decade. The definition 
by Lanza and Kennedy recognizes acute recurrent rhinosinusitis, but not 
nasal polyposis as this is considered to be a different disease (Lanza et al. 
1997). In the European Academy of Allergology and Clinical Immunology 
Task Force document (European Position Paper on Rhinosinusitis and 
Nasal Polyps, EPOS), new evidence-based definitions for these sinonasal 
disorders were recently proposed for both clinical and research purposes 
(Fokkens et al. 2007). In this definition, NP is considered to be a subgroup 
of chronic rhinosinusitis. Table 4 shows the main differences between 
these definitions of adult R (Lanza et al. 1997; Fokkens et al. 2007).
WHO organized a workshop on Allergic Rhinitis and its Impact on 
Asthma (ARIA) to make an evidence-based approach to the definitions, 
impact, diagnostics and treatments of these conditions (Bousquet et al. 
2008).
5.4.2 Rhinosinusitis in adults
Common cold, acute viral R, is estimated to affect adults 2-5 times/year 
and school children 7-10 times/year (Mackay 2008). Most colds are self-
limiting and mild. Rhinoviruses (24%, but up to 80% in seasonal epidem-
ics) and influenzaviruses (11%) are the main causative agents, but more 
than 200 viruses or viral serotypes have been described in acute URTI 
with recent sensitive detection methods (Monto 2002).
Limited data about acute rhinosinusitis (ARS) and CRS epidemiology ex-
ist since the definitions and patient selection criteria have not been uni-
form. Only 0.5-2% of acute viral URTI have been estimated to become 
complicated by a bacterial infection, but this estimate is subject to debate 
as the diagnosis of bacterial infection is often impossible to make without 
invasive procedures. Acute viral R commonly precedes bacterial infec-
tion (Heikkinen et al. 2003).  Most common bacterial species isolated 
in ARS are S. pneumoniae and H. influenzae (Poole 2004). Commonly, 
antibiotics are prescribed for ARS symptoms although bacterial sinonasal 
infection is known to be far less common than a prolonged viral infection 
(Small et al. 2007).



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Various microbial, host and environmental factors have been suggested 
to predispose to R. The role of bacteria is still a matter of debate even 
though the microbiology of the middle nasal meatus and sinuses has 
been thoroughly studied. However, both aerobic and anaerobic bacteria 
have been recovered from the affected and non-affected sides of unilat-
eral R (Bhattacharyya 2005). Anaerobic bacteria are more commonly 
found in odontogenic sinusitis. Antibiotics and nasal steroids have been 
shown to be equally effective in the treatment of ARS in adults (Meltzer 
et al. 2005). 
Fungi have also been found in both healthy and diseased human os-
teomeatal area (Fokkens et al. 2007). A range of fungal sinonasal diseases 
ranging from non-invasive fungus balls to invasive disease have been 
described (Schubert 2001). A concept of fungal antigens causing IgE or 
IgG3 mediated inflammation in the sinuses has been proposed. However, 
no causality between the presence of fungi and CRS has been established 
(Fokkens et al. 2007). The use of systemic or topical antifungal agents 
does not consistently help patients with CRS (Weschta et al. 2004; Ebbens 
et al. 2006). 
Until now, most of the microbiology of the respiratory infections has 
concentrated on studying the non-attached, planktonic bacteria. When 
attached to surface some bacterial species may produce an extracellular 
matrix called biofilm that protects them from both host immune response 
and antibiotics. Recently, more evidence has been found about the role of 
microbial biofilms as a cause of otorhinolaryngolocial infections such as 
otitis media with effusion (Macassey et al. 2008). Biofilms have also been 
suggested to be important in treatment-refractory CRS (Hunsaker et al. 
2008). 
Cigarette smoking has been suggested to associate with a high prevalence 
of CRS (Chen et al. 2003), but no convincing evidence exists for the etio-
logic role of pollutants in CRS or NP (Fokkens et al. 2007).
5.4.3 Nasal polyposis
Aspirin (ASA) sensitivity is a non-allergic syndrome caused by abnor-
mal metabolism of arachidonic acid metabolites. It involves acute al-
lergic reactions to non-steroidal anti-inflammatory drugs metabolized 
through cycloxygenase (COX) pathways. Aspirin sensitivity can cause a 
treatment-resistant form of bronchial asthma and commonly also CRS 
and NP (Fokkens et al. 2007). CRS with NP is seen in 36-96% of patients 
with aspirin sensitivity, and 96% of them have radiologic abnormalities 
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in the paranasal sinuses (Szczeklik et al. 1977; Fahrenholz 2003).  A high 
incidence of human leucocyte antigen (HLA) A1 and B8 has been re-
ported in patients with asthma and ASA sensitivity (Moloney et al. 1980). 
Contradictory reports on association of allergy and NP have been pub-
lished (Fokkens et al. 2007).
Severe primary antibody deficiencies frequently present with severe re-
current R (RRS) with or without NP (Wood et al. 2007; Herriot et al. 2008). 
The most common minor defects in adaptive immunity, IgA deficiency 
and low IgG subclass levels may predispose to CRS and RRS (Baumann 
et al. 2007). However, the clinical significance of abnormal IgG subclass 
levels in CRS patients remains unclear (Wood et al. 2007).  
In addition to relatively rare primary antibody deficiencies like X-linked 
agammaglobulinemia (XLA, caused by intracellular tyrosine kinase mu-
tations), cystic fibrosis and primary ciliary dyskinesia are the only genetic 
abnormalities linked to CRS. Cystic fibrosis is one of the most common 
autosomal recessive disorders elsewhere in the Caucasian population and 
is caused by mutations in the CFTR gene in chromosome 7 (Riordan et 
al. 1989). The mutations in CFTR have been reported to cause CRS also 
in the general population (Wang et al. 2000). Cystic fibrosis is, however, 
rarely seen in Finland (Hytönen et al. 2001).
There is a strong hereditary component in NP in family studies. The few 
existing twin studies suggest additional influence of environmental fac-
tors.  In linkage analysis and association studies some candidate gene 
polyporphisms have been associated with certain phenotypes of NP. In the 
gene coding IL-1alpha (IL1A) a single G to T polymorphism in exon 5 at 
+4845 was associated with a reduced risk of developing NP (Karjalainen 
et al. 2003). In another study IL-4 gene polymorphism (IL4/590 C-T) in 
the Korean population was associated with protection against NP (Park 
et al. 2006). Several correlations between HLA-alleles and NP have been 
presented (HLA-A74, HLA-DR7-DQA1*0201, HLA-DR7-DQB1*0202, 
DQB1*0201, HLADRB1*03, HLA-DRB1*04), but these are dependent on 
the ethnic background of the population studied (Fokkens et al. 2007).
 
Local host factors, such as sinonasal anatomical abnormalities have not 
convincingly been found to be in causal relationship with CRS although 
sinonasal complaints often resolve with surgery (Fokkens et al. 2007).
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5.4.4 Airway allergy 
Allergic disorders have been defined as an epidemic of the Western coun-
tries (Haahtela et al. 2008). Both allergic rhinitis (AR) and asthma are 
systemic inflammatory conditions and often co-exist. This has lead to the 
concept of “United Airways” where both conditions are to be evaluated 
and managed in each patient (Bousquet et al. 2008). 
Allergic rhinitis and bronchial asthma have been associated with CRS. 
The role of allergy in the development of CRS is still unclear, although 
epidemiological data shows an increased prevalence of allergic rhinitis 
in patients with CRS. There is a problem in evaluating the cause-effect 
relationship as the symptoms of CRS and allergic rhinitis partly overlap 
(Ryan 2008). Allergy is a poor prognostic factor in postoperative results 
in some, but not all studies (Meltzer et al. 2004). Abnormalities in the 
mucosa of paranasal sinuses are seen in sinus imaging in asthmatics, but 
this may reflect either allergic inflammation or infection (Fokkens et al. 
2007).
In adult Finnish population, the prevalence of physician diagnosed AR 
or allergic conjunctivitis was 41.9% and of asthma 6.9% (Pallasaho et al. 
2006). At least one skin prick test was positive in 46.9% of all subjects. In 
young adults (age 26-39) 56.8% were sensitized to at least one allergen, 
24% to at least four. Sensitization to multiple allergens was associated 
with high prevalence of asthma, AR or conjunctivitis, and wheeze. 
5.4.5 Tonsillar diseases in children 
 
Usually a larger area of the pharynx than the tonsils themselves is affect-
ed during episodes of tonsillitis/tonsillopharyngitis. These diseases are 
commonly caused by respiratory viruses, but bacterial involvement is not 
unusual. Typical bacteria found in tonsils are beta-hemolytic streptococci 
of the A, B, C or G-group, H. influenzae or staphylococci. Also yeasts and 
Actinomyces have been found in tonsils, but their pathogenicity is largely 
unknown (Wiatrak 1998). Altogether tonsils are known to harbor several 
pathogenic and non-pathogenic microbes, yet their association to tonsil-
lar diseases is not always clear. In acute tonsillitis, GAS are considered a 
significant pathogen due to their potential for systemic invasive infec-
tions and postinfectious complications (Bisno 1996; Wiatrak 1998).
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In recurrent or prolonged tonsillitis, the immunogically active reticular 
epithelial cells are replaced by squamous epithelium. This weakens anti-
gen transport, B-cell activation, and Ig production and probably makes 
an individual more susceptible to new episodes of tonsillitis (Brodsky et 
al. 1993). Recurrent tonsillitis is established if episodes recur 7 times per 
year or 5 times in consecutive years (Paradise et al. 1984).
Chronic tonsillitis is a poorly defined clinical diagnosis and is based on 
typical findings in pharyngeal inspection and possibly positive strepto-
coccal culture. Patient commonly has prolonged pharyngeal pain, en-
larged and/or painful cervical lymph nodes, halitosis, ceratosis or puru-
lent discharge from tonsillar crypts (Darrow et al. 2002).
In tonsillar hyperplasia, enlarged tonsils are seen due to hypertrophic 
lymphoid tissue. This is seen together with recurrent and chronic ton-
sillitis (recurrent tonsillitis with hyperplasia, RT-TH) but also with no 
history of infections (idiopathic tonsillar hyperplasia, ITH). RT-TH is 
considered to be a subtype of recurrent tonsillitis and ITH is possibly 
a different disease entity. Tonsillar hyperplasia may cause, depending 
on the degree of the hyperplasia, constant oral breathing, malocclusion, 
disturbances in craniofacial growth, eating disorders or speech impair-
ment. Night-time problems may include snoring, sleep-related breathing 
disorder, obstructive sleep apnea syndrome, enuresis and restless sleep 
with daytime hypersomnolence or behavioral disorders. Reliable epide-
miological data about the incidence and prevalence of tonsillar diseases 
is limited (Mattila et al. 2001; Darrow et al. 2002).
Operations of pharyngeal and palatine tonsils are still among the most 
common operations in children. The numbers of tonsillar operations 
have decreased lately in several Western countries. In children, until the 
age of 10, the most common indication for tonsillar operation is hyper-
plasia, in teenagers peritonsillar abscess and in 20-year-olds chronic ton-
sillitis (Mattila et al. 2001; Vestergaard et al. 2007). Only three systematic 
reviews about tonsillectomies have been made. The first one gives high 
rated evidence-based recommendation for outpatient surgery in prop-
erly selected children (Brigger et al. 2006). The second one showed that 
antibiotics reduced fever and the duration of halitosis and marginally the 
time to resume normal activity after operation, but had no effect on pain 
scores or the need for analgesia (Dhiwakar et al. 2008).  Instead, an in-
creased risk for adverse events due to antibiotics was observed. The third 
review showed that electrodissection increases pain in patients with no 
difference in postoperative hemorrhage rates (Leinbach et al. 2003).
REVIEW OF THE LITERATURE
40
5.5 The role of sex in immunity and respiratory diseases 
Females are more immunocompetent than males. This sexual dimor-
phism is a common feature in vertebrates and even in a number of in-
vertebrates (Nunn et al. 2009). In humans, it has long been known that 
females and males also behave differently when immunological reac-
tions and susceptibility to infections are considered. Females produce 
more vigorous humoral and cellular reactions to infections and are more 
resistant to certain bacterial infections. On the other hand, the risk for 
autoimmune disorders (such as multiple sclerosis, rheumatoid arthri-
tis, systemic lupus erythematosus and thyroiditis) is higher in females 
(Whitacre 2001; Bouman et al. 2005). This dichotomy is only partly due 
to the reproductive hormones. The interest for the study of sexual dimor-
phism has spread from autoimmune diseases to infectious diseases and 
the information about possible causative factors for these differences has 
increased.
5.5.1 Innate immunity
Effects of sex-hormones to the monocyte counts are well known. Female 
sex-hormones induce the release of monocytes from the bone marrow 
during luteal phase and pregnancy (Bain et al. 1975). Estrogen, and pos-
sibly progesterone also, seems to decrease monocyte numbers probably 
by inducing mitotic arrest and apoptosis (Thongngarm et al. 2003).
Tumor necrosis factor (TNF) is an important mediator of proinflamma-
tory responses. In males, monocytes produce more TNF, but in vitro no 
effect of testosterone on the production of TNF has been seen. In females, 
reproductive phase influences the TNF production leading to higher 
plasma levels and stronger reactions to endotoxin stimulation in the 
luteal phase (Brannström et al. 1999; Bouman et al. 2001). Interestingly, 
also after the menopause, with low levels of circulating female sex hor-
mones, TNF production is higher than in men, suggesting that factors 
other than hormones affect monocytes (Bouman et al. 2004; Bouman et 
al. 2004). When LPS stimulated TNF levels were measured in the periph-
eral blood a weaker response in females was found. This difference was 
partly HLA-independently sex-related, partly HLA-related and partly 
due to unknown reasons (Moxley et al. 2002).
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5.5.2 Adaptive immunity
Gonadal hormones (estrogens, progesterone and testosterone) can mod-
ulate immunity. Estrogen receptors are found in immune cells. Estrogen 
has a biphasic dose effect with low levels and high levels inhibiting spe-
cific immune reactions. After a challenge by an infective agent or antigen, 
females are more likely to develop a systemic Th1-type response than 
males. An exception is pregnancy, when Th2-type systemic responses 
prevail (Moxley et al. 2002). Progesterone promotes the development of 
Th2-cells and antagonizes the Th1-response. The Th1 phenotype in pe-
ripheral blood lymphocytes is slightly inhibited by estrogens and stimu-
lated by androgens (Paavonen 1994; Giltay et al. 2000).  Females have a 
more vigorous immune response with more abundant antibody produc-
tion and strong cell-mediated immunity after immunization (Bouman et 
al. 2005). Females also have more pituitary hormones (prolactin, growth 
hormone) that enhance autoimmunity. Testosterone has anti-inflamma-
tory properties and is immunosuppressive in several animal models of 
autoimmunity. Based on a murine model, it has been suggested that sex 
chromosomes and sex hormones may compensate for each other in caus-
ing immunostimulation and -inhibition (Palaszynski et al. 2005).
The actual cellular and molecular mechanisms of sex hormone actions 
on immune system are not yet clear (May 2007).  Fluctuations in hor-
mone levels during pregnancy affect the course of autoimmune diseases. 
Sex hormone treatments for autoimmune diseases have been tried with 
sometimes promising results (Schmidt et al. 2006). Females have higher 
levels of circulating IgA than males, but this difference is seen only after 
puberty: this suggests that gonadal hormones may influence IgA produc-
tion (Bouman et al. 2005). Females also have higher levels of circulating 
IgM than males. This difference is most apparent in puberty, but can be 
seen already in prepubertal children suggesting a mechanism not related 
to sex-hormones (Butterworth et al. 1967).
5.5.3 Allergic diseases  
The risk for several allergic diseases in childhood has been recognized to 
be greater in males than in females (Jensen-Jarolim et al. 2008). However, 
during the last years the difference has diminished due to an increase of 
allergic conditions which has been greater in girls (Osman et al. 2007). 
In boys a higher risk than in girls for bronchial (atopic) asthma, food 
allergy and atopic status confirmed by SPT or serum specific IgE for al-
lergens has been seen in several studies (Emmett et al. 1999; Pumphrey 
et al. 1999; Govaere et al. 2007; Jacobson et al. 2008). In adolescence this 
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is reversed, and adult females suffer from more respiratory allergies, food 
allergy and asthma (Chen et al. 2008). This change may at least partly 
be caused by sex-hormones. Estradiol has been shown to increase mast 
cell activation and allergic sensitization in a rodent model (Yamatomo et 
al. 2001; Melgert et al. 2005). Progesterone supresses histamine release 
but potentiates IgE formation (Vasiadi et al. 2006; Mitchell et al. 2007). 
A male sex hormone, dehydroepiandrosterone, downregulates Th2 cy-
tokine production but does not affect IgE levels (Sudo et al. 2001; Yu et 
al. 2002). 
5.5.4 Respiratory infections 
Both the incidence and the severity of respiratory infections are different 
in females and males. Generally, females get more infections of the up-
per respiratory tract, especially sinusitis and tonsillitis (Table 5) (Falagas 
et al. 2008). Males are more often suffering from otitis media, laryngeal 
croup and LRT infections. In females the course of the disease is usually 
less severe.  In contrast, males suffer from more complicated diseases and 
have a higher mortality, especially due to community-acquired pneumo-
nia.
5.5.4.1 Sinonasal infections
Females appear to catch common cold and acute sinusitis more often 
than males (Gonzales et al. 1997; Lieu et al. 2000; Stalman et al. 2001; 
Chen et al. 2003; Shashy et al. 2004; Xatzipsalti et al. 2005; Barrett et al. 
2007). Recurrent R (Bhattacharyya et al. 2005; Poetker et al. 2008) and 
CRS without polyposis  (Collins et al. 2002; Shashy et al. 2004) occur 
more often in females than in males. On the other hand, CRS with poly-
posis is more common in males (Fokkens et al. 2007). 
5.5.4.2 Tonsillar infections 
In several studies acute/recurrent tonsillitis has more commonly been 
seen in female than male patients (Thorp et al. 2000; Lin et al. 2003; 
Kvestad et al. 2005). In males, peritonsillar abscesses were more common 
(Matsuda et al. 2002).
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In a very interesting study from Denmark, 153 212 tonsillectomies per-
formed between years 1980 and 2001 were reviewed (Vestergaard et al. 
2007). The results showed that there were two peak ages for tonsillecto-
my. The first peak was at 4 years of age. For boys, 9.7 operations per 1000 
person years were performed. For girls, the figure was 6.9. Male to female 
ratio was 1.41. The second peak was during adolescence, in girls at 16 
years (8.6/1000 person years operated) and in boys at 17 years (3.1/1000). 
Male to female ratio was 0.36. From 8 years to 40 years of age females 
were operated more often, but after 40 years of age the operation rate was 
smaller in females (0.13 females vs. 0.16 males/1000 person years oper-
ated). The overall male to female ratio for all ages was 0.81/1000 person 
years. Similar results have been obtained from other studies but the rea-
sons for these sex differences have remained unknown (Freeman et al. 
1982; Mattila et al. 2001). 
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Table 5. Sex-associated differences in the incidence of upper respiratory 
tract infections.
5.6 Rhinoviruses
Common cold i.e. an acute viral URTI is the most common illness in 
humans, occurring twice as frequently as the next common condition. 
URTIs are caused by several different respiratory viruses, human rhino-
viruses (HRVs) being the most common (Puhakka et al. 1998; Heikkinen 
et al. 2003; Arnold et al. 2008; Peltola et al. 2008). HRV causes up to 34 
% of all URTIs, and during its main peak season (September-October 
following the opening of schools) even up to 80% and during the sec-
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ondary peak season (April-May) up to 30% of URTIs. Although not an 
indication, HRVs are the most common reason for prescribing antibiot-
ics for respiratory illness, exceeding even bacterial infections (Rotbart et 
al. 2000). Another very important fact in HRV morbidity is that it is the 
most common cause for wheezing in children and asthmatics (Rotbart et 
al. 2000; Monto 2002; Papadopoulos et al. 2002; Jartti et al. 2004; Jacques 
et al. 2006).
Over 100 serotypes of human rhinoviruses (HRVs) have been recog-
nized. HRV is an RNA virus with adenine and uracil (A+U) rich cap-
sid. This capsid of most of the HRVs interacts with the amino-terminal 
domain of the 90 kDa adhesion molecule ICAM-1/CD54 (Greve et al. 
1989; Staunton et al. 1989; Tomassini et al. 1989; Rossmann et al. 2000). 
Receptor binding destabilizes the capsid and initiates uncoating. A mi-
nor group of HRVs use members of host low-density lipoprotein receptor 
(LDLR) family for attachment and use a different destabilization method 
for uncoating of the virus.
The transmission of HRVs occurs both directly via airborne aerosol and 
large droplets and through indirect contacts with contaminated secre-
tions. Both routes are important, and therefore hand disinfection can 
only give partial protection. Crowding increases transmission. URTI hits 
especially little children, with a yearly incidence of 5-7 in 1-2 year old 
children. A decrease in incidence after the age 5-9 years is seen followed 
by a slight increase especially in females at 20-29 years. This may reflect 
an exposure to young children known to be able to infect their parents 
(Lidwell et al. 1951; Monto 2002). URTI has been shown to be more fre-
quent in males up to 3 years of age and in girls thereafter (Monto 1994).
Rhinovirus RNA is taken into the cell mostly through the ICAM-1 
(CD54) receptor. This cell surface glycoprotein is present on antigen-pre-
senting cells, lymphocytes, eosinophils, mast cells, submucosal glands, 
airway smooth muscle cells, and epithelial cells. The function of ICAM-1 
is to regulate leukocyte trafficking and accumulation at sites of inflamma-
tion. Rhinovirus infection upregulates the expression of ICAM-1 and in-
duces a rapid increase in serum IgE levels. In contrast, HRV has not been 
found to elevate antigen-specific IgE levels in allergic subjects (Skoner et 
al. 1995).
Symptoms of HRV infections develop within days of virus inoculation 
(Holmes et al. 1976). Sneezing, nasal disharge (rhinorrhea), nasal conges-
tion/blockage, sore or irritated throat, headache, cough, feeling of fever 
and malaise are common symptoms (Mackay 2008). Also loss of taste and 
smell, hoarseness, body aches and pains, feeling of pressure in the ears 
and sinuses, mild burning feeling in the eyes, anorexia and loose stools 
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have been reported (Mackay 2008). Even a self-limiting asymptomatic si-
nusitis may be associated with common cold, most often caused by acute 
HRV infection (Puhakka et al. 1998).  Fever is more common in children 
(Miller 1955; Dick et al. 1967). In children, even uncharacteristic irrita-
bility, disturbed sleep patterns and feeding difficulties due to snuffles can 
be seen (Mackay 2008). The treatment of HRV infections is most com-
monly symptomatic. Decongestants, analgesics, antihistamines, nasal 
steroids and antitussives have been used, but no HRV-targeted medica-
tion is commercially available at the moment.
HRV has been detected in the lower respiratory tract (LRT) (Papadopoulos 
et al. 2000), causing acute wheezing episodes in children, especially among 
males and during the first year of life (Mackay 2008). Also in adults over 
40 years of age respiratory infections caused by HRV associate with long-
er and more frequent LRT illnesses causing nearly two thirds of the total 
burden of respiratory illness (Monto et al. 1987). HRVs have long been 
associated with AOM (Arola et al. 1990; Vesa et al. 2001). They have been 
detected in the middle ear fluid even in the absence of bacteria during 
AOM (Sung et al. 1993). In nasopharyngeal swabs of symptomatic and 
asymptomatic AOM-prone children up to 30% detection rate of picorna-
virus has been seen (Pitkäranta et al. 2006). By using in situ hybridization 
HRV RNA has been found in 45% (up to 65% during season) of adenoid 
tissues from children with recurrent AOM (Rihkanen et al. 2004). HRV 
RNA has also been detected in the maxillary sinus during acute sinusitis 
(Pitkäranta et al. 2001). 
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6 AIMS OF THE STUDY
The general aim of these studies was to evaluate different aspects of the 
host immunity and pathogens in selected upper respiratory infections 
commonly leading to operations. Factors from both innate and adaptive 
immunity of the host were analyzed according to clinical findings. 
Specifically, the study objectives were as follows:    
1. Are there differences between the phenotypes of females and males 
coming for operative treatment for sinonasal diseases?
2. Is there an association between sinonasal diseases and complement 
upregulation?
3. Are sinonasal diseases associated with genetic deficiencies of C4 or low 
serum/plasma levels of immunoglobulins?
4. Does previous adenoidectomy in children modify the development of 
specific IgE-sensitization or allergic diseases later in life?
5. Is the clinical tonsillar disease in tonsillectomy patients associated with 
host immune evasion by complement regulator binding of tonsillar group 
A streptococci?
6. Can human rhinoviruses invade palatine tonsillar tissue and modify 
tonsillar disease?
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7 SUBJECTS AND METHODS     
   
7.1 Study subjects and ethical considerations 
The patients for these prospective studies were recruited from the Helsinki 
capital area and surrounding communities belonging to the Hospital 
District of Helsinki and Uusimaa (Table 6).
Table 6. Subjects in studies. F = Female; M = Male
1Material: Q, questionnaire; S, serum; B, bacterial; D, DNA; b, biopsy; CT, computed tomography 
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The study protocols were approved by the ethics committees of the respec-
tive clinical units (Diary numbers 6/E5/2001, 647/E9/01, 245/E9/02), and 
an informed written consent was obtained from all subjects. One patient 
coming to sinonasal operations was found to have common variable im-
munodeficiency, and after an ethics committee approval the patient was 
informed about the disease and referred to the Immunodeficiency Unit, 
Division of Infectious Diseases, Department of Medicine for treatment.
7.2 Bacterial strains
In addition to bacterial culture samples from patients, five random GAS-
strains from positive blood cultures (collected during 2003) and five 
T1M1 strains, collected and typed during years 2002-2004 at the Helsinki 
University Central Hospital laboratory (HUSLAB), were selected for 
comparison with tonsillar GAS strains.
7.3 Data collection and diagnostic definitions
Patients coming to operations (I-V) filled out a questionnaire (Appendices 
1, 2 and 3) about their symptoms, history of respiratory diseases, previ-
ous sinonasal operations, the use of medication during the preceding 12 
months and doctor-diagnosed allergy and asthma.
As acute sinusitis patients (study I) we recruited consecutive voluntary 
patients with R symptoms lasting over 7 days and fluid level or opacity 
in a plain sinus radiograph or purulent discharge in sinus puncture with 
lavage. For inclusion they had to have no previous R episodes lasting over 
3 months and less than 4 yearly episodes of purulent R. 
Inclusion criteria for chronic R group (sCRS) (study I) were: no clear 
response to sinonasal surgery other than septoplasty, to short-course an-
tibiotics or to maximal topical medical management. Patients fulfilled 
Rhinosinusitis Task Force 1997 criteria (Table 4) (Lanza et al. 1997). 
Exclusion criteria for both patient groups in study I were: age less than 18 
years, pregnancy, lactation, imprisonment or military service or mental 
retardation.
Inclusion criteria in sinonasal operation (either endoscopic sinus surgery 
or polypectomy) patients (SNO) (study II) were: prolonged maxillary si-
nusitis (over 3 months), recurrent maxillary sinusitis (more than 4 times 
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during one year) and/or sinonasal polyposis. Diagnosis was confirmed 
either with computed tomography (CT) or endoscopy. Exclusion crite-
ria were as in study I. The diagnosis of CRS and RRS were defined as 
proposed by the American Academy of Otolaryngology–Head and Neck 
Surgery (Lanza et al. 1997). Patients were divided into different diagno-
sis groups as follows. Nasal polyposis was diagnosed preoperatively by 
nasal endoscopy, and when there were no history, symptoms or signs of 
sinus infections a classification nasal polyposis only (NPO) was defined. 
Chronic R with nasal polyposis (CRSwNP) was defined if a patient with 
chronic R had visible middle meatal polyposis preoperatively.  Chronic 
R without nasal polyposis (CRSsNP) was defined when symptoms of 
chronic sinusitis had been present for over 12 weeks but no polyps were 
seen preoperatively. Recurrent R (RRS) was defined as recurrent episodes 
(more than 4/year) of acute bacterial sinusitis. The CRS and RRS patients 
were analyzed together under the term CRS. The definitions of CRSsNP 
and CRSwNP are not fully concordant with the later published EPOS 
classification, as this does not recognize recurrent R (Fokkens et al. 2007). 
Available CT scans were scored according to Lund-Mackay system (Lund 
et al. 1993). In Lund-Mackay system sinuses are individually scored in a 
following scale: 0=no opacification, 1=partial opacification, 2=complete 
opacification of each paranasal sinus and for osteomeatal unit patency: 
0=open, 2=blocked.  Lund-Mackay CT score ranges from 0 (no mucosal 
changes in any of the sinuses) to 24 (total opacification of all sinuses) 
points.
Inclusion criteria in tonsillectomy patients (n=213) (studies III-V) were: 
recurrent tonsillitis (at least 6/year or 3/year for 2 consecutive years, with 
at least one positive culture for GAS), or a clinical diagnosis of either 
chronic tonsillitis (prolonged tonsillar infection refractory to antimicro-
bial therapy) or tonsillar hyperplasia (enlarged tonsils with symptoms). 
For enrollment, children had to be without acute respiratory symptoms at 
the time of the operation. Not uncommonly, a child has tonsillar hyper-
plasia simultaneously with recurrent or chronic tonsillitis, which are all 
indications to operate. In study IV all indications for the operation were 
recorded, but the indication to operate was systematically determined: 
hyperplasia if no chronic or recurrent infections were noted, chronic ton-
sillitis if not connected with recurrent episodes of acute tonsillitis, and 
recurrent tonsillitis with recurrent episodes of acute exacerbations.
Pediatric controls (n=155) (study III) were randomly selected as follows: 
the pupils were given an ordinal number according to an alphabetical 
list of their family names. Thereafter, first an initial number was selected 
from a table of random figures and then every 10th pupil from each class 
level was chosen. Exclusion criterion was refusal at any stage. Only one 
child from each family was included.
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Healthy controls (n=48) (study I) were selected from a pool of healthy 
blood donors (n=100) to match in age and sex with chronic R patients. 
These subjects had no self-reported history of R fulfilling the published 
criteria (Lanza et al. 1997). Exclusion criteria were the same as for pa-
tients.
Unselected controls (n=150) (studies I and II) were consecutive voluntary 
subjects coming for a health survey before accepting a new occupational 
post, again with the same exclusion criteria.
       
7.4 Sample collection, processing, and storage
     
Blood samples were drawn from each patient (studies II-V) during the 
operation and serum was separated in the laboratory of the Clinic of 
Otolaryngology, Head and Neck Surgery. In study I the patient samples 
were obtained from the laboratories of the Helsinki University Central 
Hospital (HUSLAB).  From pediatric controls blood was drawn and se-
rum separated by laboratory personnel at site. From adult controls and 
acute sinusitis patients the samples were taken in the corresponding labo-
ratories. Specimens were frozen first at -20°C and transported in dry ice 
to the research laboratory and kept at -70°C. Genomic DNA was iso-
lated from blood leukocytes with commercial kits (QIAamp Blood Kit, 
Qiagen, Austria and Puregene Kit, Gentra Systems, USA). Serum, blood 
and DNA samples were kept in -70°C. Details of sampling procedures are 
provided in the individual publications (I-V).
Tonsil samples were obtained from pediatric tonsillectomies (studies 
III-V). Half of the removed tonsil was snap-frozen by immersing in iso-
pentane cooled with liquid nitrogen. After freezing the samples were kept 
in -70°C. The other half of the tonsil was cut into smaller pieces. From 
patients 51-83 (Study V) one piece was immersed in formaldehyde for 
in-situ examination and another was ground and cultured in blood agar 
plates incubated aerobically in 37°C. Standard procedures were used to 
determine growth of aerobic bacterial pathogens and yeasts. Streptococci 
were identified and the strains were stored at -70°C. The T and M serotyp-
ing of GAS strains from tonsillar tissue and blood was performed in the 
laboratory of the Department of Bacterial and Inflammatory Diseases, 
National Public Health Institute.
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7.5 Analytical methods       
 
Analytical methods used in each study are described in more detail in 
each article and summarized in Table 7.
7.5.1. Levels of complement components and immunoglobu-
lins
Serum and plasma concentrations of C3 and C4 (Study I and II) were 
measured by nephelometry (Behringwerke AG, Germany). Serum CH50 
(Study I) was analyzed by enzyme-linked immunosorbent assay (ELISA) 
technique (Quidel Corp, CA, USA). Serum immunoglobulins IgG, IgM, 
and IgA were measured by nephelometry using the reagents and BN 
ProSpec Analyzer from Dade Behring (Marburg, Germany). IgG sub-
classes were measured by nephelometry with Behring BNA Analyzer us-
ing PeliClass reagents (Sanquin, Amsterdam, The Netherlands). 
For studies on IgE sensitization the specific IgE levels in the patients’ sera 
were screened with the Phadiatop® (Pharmacia Diagnostics AB, Uppsala, 
Sweden) laboratory kit. Positive samples were further analyzed for spe-
cific IgE against the following common respiratory allergens in Finland: 
birch, house dust mite (Dermatophagoides pteronyssimus), cat, dog, horse, 
timothy, mugwort and mold (Alternaria alternata) using Pharmacia CAP 
System® (Pharmacia Diagnostics AB, Uppsala, Sweden) (Paganelli et al. 
1998). A level of 0.35 kU/l or more of specific serum IgE was considered 
positive. 
7.5.2. C4A and C4B typing 
Allotyping of C4A and C4B was performed electrophoretically from 
carboxypeptidase B (Roche Diagnostics Gmbh, Mannheim, Germany) 
and neuraminidase (Sigma-Aldrich Chemie Gmbh, Type IV, Steinheim, 
Germany) treated serum samples followed by immunofixation with poly-
clonal anti-C4 antibody (DiaSorin Inc., Stillwater, MN, USA) with the 
standard procedure (Marcus D 1996). C4A and C4B allotypes were run 
to specific positions on the gel in relation to the standards. The presence 
of ≤ 1 C4A or C4B variants were defined as nulls.
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The copy number variations of C4A and C4B genes were analyzed by 
isotype-specific genomic real-time polymerase chain reaction (RT-PCR) 
(Seppänen et al. 2006). C4A pseudogene caused by a 2-base pair inser-
tion in exon 29 (codon1213) was analyzed by sequence specific RT-PCR 
(Barba et al. 1994). We used unlabeled primers with SYBR Green QPCR 
(Stratagene, Cedar Creek, Texas, USA) or Absolute QPCR SYBR GREEN 
MIX (Abgene, Epsom, UK) according to the manufacturers’ instructions 
with minor modifications. The presence of one or less functional C4A or 
C4B gene defined a deficiency.
7.5.3. GAS typing and binding of C regulators
Factor H (Calbiochem) and C4BP (a gift from Dr.Anna Blom, University 
of Lund, Sweden) proteins were radiolabeled with 125I using the Iodogen 
method for use in the binding assays (Salacinski et al. 1981). GAS strains 
were grown overnight in Todd-Hewitt broth, washed three times with 
veronal-buffered saline, containing 0.1% gelatin (GVB). C4BP binding 
assays were done in GVB and FH binding assays in 1/3 GVB. The bac-
terial concentration was adjusted to 9.5 x 108/ ml. A total of 20 µl por-
tions of the suspension (containing 1.9x107 bacteria) were mixed with 
125I -labeled FH or 125I -labeled C4BP and incubated for 30 min at 37ºC. 
Bacteria-bound and free radioactive proteins were separated by cen-
trifuging the samples through a 250 µl column of 20% sucrose in GVB 
(C4BP) or 1/3 GVB (FH). The bottoms of the tubes were cut out and radi-
oactivities in both the supernatants and the pellets were measured using 
a gammacounter. Binding is expressed as percentage of the radioactivity 
in pellet vs total radioactivity (pellet+supernatant). All experiments were 
performed in triplicate or quadruplicate.
T serotypes and emm types were determined in GAS strains cultured 
from tonsils or blood. T serotyping was performed using five polyva-
lent and 21 monovalent anti-T-agglutination sera  (Sevac Ltd., Czech 
Republic) (Moody et al. 1965) . M-protein type was determined with 
emm sequence typing using primers MF1 (forward) and MR1 (reverse): 
for emm-PCR (Siljander et al. 2006). PCR products were purified with the 
QIAquick PCR purification Kit (Qiagen) as described by the manufac-
turer. The emm-sequencing reaction was performed with the primer MF1 
and BigDye chemistry (Applied Biosystems) as described by the manu-
facturer, and analyzed with an ABI Prism 310 Genetic Analyzer (Applied 
Biosystems). The sequence data was analyzed by BLAST search against 
S. pyogenes emm sequence database at Centers for Disease Control and 
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Prevention (CDC). The emm-types were defined as having 95% sequence 
identity with the exact 150 base type-specific sequences in the database as 
described at the CDC website. 
7.5.4. Detection of rhinoviruses
Preparation of the rhinovirus-14 probe and the in-situ hybrization (ISH) 
protocol were based on published procedures (Pitkäranta et al. 2001) The 
result in ISH was considered positive when the hybridization signal was 
visible as cytoplasmic reactivity in more than 10% of either epithelial or 
lymphoid cells. The specificity of the ISH signal was verified by in vitro 
infection of HeLa cells with rhinovirus-14. Uninfected HeLa cells were 
negative both by the antisense and by the sense probe. It should be noted 
that although the genomic region exploited was designed to be HRV spe-
cific we cannot totally exclude partial cross-reactivity with some human 
enterovirus (HEV) strains. The results were evaluated in a blind manner 
from coded slides and the evaluators had no information about the PCR 
or culture results, or the clinical background of the patient.
We used two different reverse transcription polymerase chain reaction 
(RT-PCR) methods for HRV/HEVRNA detection. DNA amplification 
was done in parallel with two different methods. In the conventional 
PCR-hybridization assay (PCR-HYB) the polymerase reaction was car-
ried out on microtiter plates as described earlier (Blomqvist et al. 1999). 
The other method used was a single-tube nested PCR, a hanging drop 
version (nested PCR) modified from that described by Walsh and Ratcliff 
(Walsh et al. 2001; Ratcliff et al. 2002). 
SUBJECTS AND METHODS
55
Table 7. Laboratory methods used in the studies.
7.6 Statistical analyses      
 
In studies I, II and III, χ2 (Chi-square) and Fisher’s exact two-tailed tests 
were used for analysis of differences in categorical data between groups, 
as appropriate. Mann-Whitney U-test was used for comparing continu-
ous data in studies IV and V. Forward stepwise logistic regression analysis 
was used in studies I, IV and V to identify the influence of different pre-
dictors to clinical symptoms and forms of disease. In study I comparisons 
between all groups in continuous variables were performed by nonpara-
metric analysis of variance (Kruskal–Wallis test, Jonkcheere–Terpstra 
test for ordinal groups), as most variables had non-normal distribution in 
at least one group. If the variance analysis showed significant differences 
between groups, the two-tailed Student’s t-test with Bonferroni correc-
tion was employed. In study I the analysis of C4Q0 frequencies between 
study groups, odds ratios (OR) and 95% confidence interval (CI) were 
calculated using EpiInfo version 6, and tested using logistic regression 
analysis.
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methods for HRV/HEVRNA detection. DNA amplification was done in parallel with 
two different methods. In the conventional PCR-hybridization assay (PCR-HYB) 
the polymerase reaction was carried out on microtiter plates as described earlier 
(Blomqvist et al. 1999). The other method used was a single-tube nested PCR, a 
hanging drop version (nested PCR) modified from that described by Walsh and 
Ratcliff (Walsh et al. 2001; Ratcliff et al. 2002).  
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Statistical analyses were performed using SPSS 12.0.1. for Windows 
(studies I and III) and  SPSS 16 for Mac (study II) (SPSS Inc., Chicago, 
IL, USA) and Statsdirect (studies II, III, IV and V) statistical softwares 





8.1 Clinical and laboratory findings in adult patients with 
sinonasal diseases
8.1.1 Overall clinical observations between adult patient 
groups (studies I and II)
To analyze clinical features in various sinonasal diseases a large data pool 
from 287 adult patients with different clinical forms of the diseases was 
collected. From this data, comparisons on the special features and sex 
differences between each studied group could be made. Clinical charac-
teristics of the different patient groups with sinonasal diseases are shown 
in Table 8a and 8b.
CRSsNP patients were younger than all other SNO patients [(p<0.001 in 
females (F) and males (M)]. In females CRSsNP patients and in males 
ARS patients were the youngest. The median ages of both female and 
male patients with polyposis were higher than those of all other patient 
groups. 
Positive smoking history was common in SNO patients (57% F; 60% M) 
and ARS patients (F 54%, M 73%), but uncommon in severe sinusitis 
patients (F 30%, M 20%), (p=0.008 F, p=0.005 M). Current smokers were 
most commonly found in ARS (F 36%, M 36%) and NPO (F 33%, M 
31%) patients. 
 
The frequency of allergic symptoms varied largely between different sino-
nasal disease groups but only little between females and males. Reported 
allergic symptoms were very common (>50%) in all SNO patients, but 
uncommon in female ARS patients (15%) (p<0.001). Non-steroidal anti-
inflammatory drug (NSAID) intolerance was more common in patients 
with NPO (F 25%, M 31%) and in patients with sCRS (F 27%, M 33%) 
than in patients with ARS (F 0%, M 0%) (p=0.010 F, p=0.04 M; p<0.001 
F, p=0.052 M, respectively) or CRSsNP (F 0%, M 3%) (p=0.003 F, p=0.004 
M; p<0.0001 F, p=0.011 M, respectively). Bronchial asthma in females 
was most common in CRSwNP patients (65%) and least common in 
ARS (10%) (p<0.001) and CRSsNP (26%) (p=0.003) patients. In males 
bronchial asthma was most common in severe sinusitis patients (60%) 
and least common in acute (0%) (p<0.001) and CRSNP (10%) (p<0.001) 
patients. Specific IgE to respiratory allergens in SNO patients was more 
common in males than females (F 28%, M 42%) (p= 0.047) .
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The extent of both visual and radiological mucosal changes in nose and 
paranasal sinuses was associated to sex and to the chronicity of the dis-
ease. Nasal polyposis was more common in all severe sinusitis (F 55%, M 
73%) patients than in acute sinusitis (F 8%, M 0%) patients (p<0.001 for 
both). It was also more common in male SNO patients than female SNO 
patients (F 33%, M 67%, p<0.001). CT scores, indicating the extent of 
the mucosal disease, were lowest in female patients with severe CRS (CT 
score median=7) and CRSsNP (CT score median=9). Only in CRSwNP 
the female patients had higher CT scores (F 16, M 14) than males, all 
other groups had lower scores in females than males.
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Table 8. Clinical findings and comorbidities in adult patients with sinonasal 


















































Number of patients 97 65 20 12  33  39  
 
 





















55 (57) 33 (51) 13 (65) 9 (75)  10 (30)  21 (54)  0.0393 
Current smoker  
 
19 (20) 13 (20) 2 (10) 4 (33)  2 (6)  14 (36)  0.0113 
Allergic symptoms 
 
62 (64) 40 (62) 15 (75) 7 (58)  24 (73)  6 (15)  <0.0013 
NSAID-intolerance 
 
7 (7) 0 (0) 4 (20) 3 (25)  9 (27)  0  <0.0014 
Specific IgE to 
respiratory allergens 
 
27 (28) 20 (31) 4 (20) 3 (25)  5  5  0.6263 
Exposure to nasal 
irritants 
 
26 (26) 16 (25) 7 (35) 3 (25)  10 (30)  8 (21)  0.6052 
Nasal polyposis 
 




14 (14) 10 (15) 1 (5) 3 (25)  5 (15)  1 (3)  0.1164 
Nasal fractures 
 
3 (3) 2 (3) 0 (0) 1 (8)  0 (0)  1 (3)  0.4803 
Nasal steroid use 
 




21 (22) 15 (23) 4 (20) 2 (17)  1 (3)  0 (0)  0.00374 
Bronchial asthma 
 
36 (37) 17 (26) 13 (65) 6 (50)  18 (55)  4 (10)  <0.0013 














5  <0.0012 
1 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
2Mann-Whitney U-test  
3 Chi-square test 
4 Fisher’s exact test 
5 not recorded 
6 part of group definition 
RESULTS
Table 8a and 8b. Clinical findings and comorbidities in adult patients with 
sinonasal diseases. I=patients from study I, II=patients from study II.
8a. Females
1 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, 
sCRS = severe chronic rhinosinusitis, ARS = acute/intermittent (presumed bacterial) rhinosinusitis
2  Mann-Whitney U-test 
3 Chi-square test
4 Fis r’s exact test
5 not recorded
6 part of group definition
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8b. Males
1 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, 
sCRS = severe chronic rhinosinusitis, ARS = acute/intermittent (presumed bacterial) rhinosinusitis
2Mann-Whitney U-test 
3 Chi-square test
4 Fisher’s exact test
5 not recorded
6 part of group definition
RESULTS
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B. Males 
 














































Number of patients 92 30 26 36  15  11  
 
 





















55 (60) 19 (63) 14 (54) 22 (61)  3 (20)  8 (73)  0.0373 
Current smoker 
 
23 (25) 5 (17) 6 (23) 11 (31)  0 (0)  4 (36)  0.1083 
Allergic symptoms 
 
48 (52) 16 (53) 15 (58) 27 (75)  10 (66)  4 (36)  0.1453 
NSAID-intolerance 
 
15 (16) 1 (3) 3 (12) 11 (31)  5 (33)  0 (0)  0.0054 
Specific IgE to 
respiratory allergens 
 
39 (42) 10 (33) 11 (42) 18 (50)  5  5  0.3943 
Exposure to nasal 
irritants 
 
28 (30) 9 (30) 10 (38) 9 (25)  5 (33)  3 (27)  0.8434 
Nasal polyposis 
 




29 (32) 6 (20) 9 (35) 14 (39)  5 (33)  1 (9)  0.2463 
Nasal fractures 
 
10 (11) 5 (17) 3 (12) 2 (6)  0 (0)  2 (18)  0.2874 
Nasal steroid use 
 




21 (23) 8 (19) 4 (15) 9 (25)  0 (0)  2 (18)  0.2313 
Bronchial asthma 
 
34 (37) 3 (10) 12 (46) 19 (53)  9 (60)  0 (0)  <0.0013 














5  <0.0012 
1 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
2Mann-Whitney U-test  
3 Chi-square test 
4 Fisher’s exact test 
5 not recorded 
6 part of group definition 
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8.1.2 Sex differences in respiratory and mucosal infections 
(study II)
Although the inclusion criteria for females and males coming to sinona-
sal operations were the same, they presented with remarkably different 
pattern of past and present infectious diseases. The differences between 
female and male SNO patients are shown in Figure 5.
As an indication for operation females had more often CRSsNP (F 67% vs 
M 33%, p<0.001) and males NPO (M 39% vs F 12%, p<0.001). No differ-
ences were seen in CRSwNP (F 21% vs M 28%). Females reported more 
sinusitis (F 86% vs. M 56%, p<0.001) and use of antibiotics for sinusitis 
(F 90% vs M 71%, p=0.002). There was also a significant difference in the 
number of courses of antibiotics prescribed during the preceding year 
(mean F 4.1 vs. M 2.3, P<0.001).
Acute otitis media (AOM) at over 3 years of age was reported by 24% 
of females and by 7% of males (p=0.002), and otitis media with effusion 
(OME) by 14% of females and by 4% of males (p=0.040). Adenoidectomy 
had been done to 30% of females and 16% of males (p=0.032). Chronic or 
recurrent tonsillitis was reported by 25% of females and by 7% of males 
(p=0.001). 25% of females and 8% of males reported of being prone to 
develop periodontitis  (p=0.002) and 14% of females and 5% of males of 




Figure 5. Differences in respiratory infections between females and males 
coming to sinonasal operations. 
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Figure 5. Differences in respiratory infections between females and males coming 
to sinonasal operations.  
 
 
CRSwNP = chronic rhinosinusitis with nasal polyposis, CRSsNP  = chronic rhinosinusitis without 
nasal polyposis, NPO = nasal polyposis only, ASA = aspirin (acetylsalicylic acid), AOM=acute otitis 
media, OME=otitis media with effusion 
 
8.1.3. Complement C3, C4 and CH50 levels in rhinosinusitis patients 
 
Complement component levels are able to indicate ongoing inflammation. Serum C3 
and C4 levels and complement classical pathway activity (CH50) were found to be 
elevated in male and female patients with ARS, when compared to all other groups or 
controls (p<0.001 for all). C3 and C4 levels were elevated only in males but not in 
females when SNO patients were compared with controls (p<0.001 and 0.096 
CRSwNP = chronic rhinosinusitis with nasal polyposis, CRSsNP  = chronic rhinosinusitis without 
nasal p l , s l oly osis only, S   s irin (acetylsalicylic acid), AOM=acute o tis 
media, OME=otitis media with effusion
8.1.3. Complement C3, C4 and CH50 levels in rhinosinusitis pa-
tients
Complement component levels are able to indicate ongoing inflamma-
tion. Serum C3 and C4 levels and complement classical pathway activ-
ity (CH50) were found to be elevated in male and female patients with 
ARS, when compared to controls (p<0.001 for C3, C4 and CH50) or to 
all other groups (p<0.001 for C3, C4). C3 and C4 levels were elevated 
only in males but not in females when SNO patients were compared with 
controls (p<0.001 and 0.096 respectively). Table 9a and 9b.
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8.1.4 Plasma immunoglobulin levels in rhinosinusitis patients 
As females and males have been suggested to mount different adap-
tive immunity responses, total plasma Ig levels were studied to find out 
whether differences in antibody levels could be related to the different 
phenotypes of sinonasal disease between females and males. Differences 
in mean plasma values of Igs and the number of values below reference 
(VBR; mean-2SD) in females and males are shown in Table 9a and 9b.
 
When all SNO patients were analyzed together against all controls (Study 
II) lower levels of IgG (p=0.010), IgG1 (p<0.001), IgG3 (p=0.015), and 
more values below reference (VBR) for IgG (p=0.004), IgG1 (p<0.001), 
IgG3 (p=0.003) were seen. SNO patients had higher levels of IgA (p=0.003) 
and IgG2 (p=0.004) than controls. In all female SNO patients, lower lev-
els of IgG (p=0.02), IgG1 (p<0.001) and IgG3 (p=0.009) were found when 
compared to female controls. This phenomenon was most pronounced in 
female CRSwNP patients.  Also higher levels of IgG2 (p=0.034) were seen 
in all female SNO patients when compared to female controls. When VBR 
were compared, female SNO patients had more VBR in IgG1 (p<0.001) 
and male SNO patients more VBR in IgG3 levels (p=0.014) than their 
sex-matched controls. IgG4 levels in male CRSsNP patients were lower 
than in male NPO patients. In female patients with ARS, levels of to-
tal IgG (p<0.001), and of subclasses IgG1 (p=0.004) and IgG3 (p=0.008) 
were lower than in female controls. In males this difference was not sig-
nificant. 
Higher levels of IgA were seen in females with NPO (p=0.02) and lower 




Table 9a and 9b. Complement C3 and C4 and immunoglobulin levels in pa-
tients with sinonasal disease. Mean serum or plasma values in patients and 
controls are shown. Values in parenthesis indicate the number of values be-
low reference. I= patients from study I, II= patients from study II, n= number 
of patients within group.
9a. Females
 
1 Except for CH50 (IU/ml) all values are shown as g/l. 
2 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, 
ARS = acute/intermittent (presumed bacterial) rhinosinusitis
3 Comparisons between mean level values were made with nonparametric ANOVA (Kruskall-
Wallis) and those between numbers of values below reference with §Chi-square and #Fisher’s 
exact text. & When appropriate, mean values were compared with Student’s t-test with Bonferroni 
correction. * p<0.05, ** p<0.01 as compared with controls
4 Values ≥200 IU/ml counted as 200
5 Not recorded 
RESULTS
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Table 9. Complement C3 and C4 and immunoglobulin levels in patients with 
sinonasal disease. Mean serum or plasma values in patients and controls are 
shown. Values in parenthesis indicate the number of values below reference. I= 





1 Except for CH50 (IU/ml) all values are shown as g/l.  
2
 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = chronic 
rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, ARS = acute/intermittent (presumed bacterial) rhinosinusitis 
3 Comparisons between mean level values were made with nonparametric ANOVA (Kruskall-Wallis) and those between 
numbers of values below reference with §Chi-square and #Fisher’s exact text. & When appropriate, mean values were compared 
with Student's t-test with Bonferroni correction. * p<0.05, ** p<0.01 as compared with controls 
4 Values ≥200 IU/ml counted as 200 
5 Not recorded  

























































































































































































1 Except for CH50 (IU/ml) all values are shown as g/l. 
2 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, 
ARS = acute/intermittent (presumed bacterial) rhinosinusitis
3 Comparisons between mean level values were made with nonparametric ANOVA (Kruskall-
Wallis) and those between numbers of values below reference with §Chi-square and #Fisher’s 
exact text. & When appropriate, mean values were compared with Student’s t-test with Bonferroni 
correction. * p<0.05, ** p<0.01 as compared with controls
4 Values ≥200 IU/ml counted as 200
5 Not recorded 





































1 Except for CH50 (IU/ml) all values are shown as g/l.  
2 All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = chronic 
rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, ARS = acute/intermittent (presumed bacterial) rhinosinusitis 
3 Comparisons between mean level values were made with nonparametric ANOVA (Kruskall-Wallis) and those between 
numbers of values below reference with §Chi-square and #Fisher’s exact text. & When appropriate, mean values were compared 
with Student's t-test with Bonferroni correction. * p<0.05, ** p<0.01 as compared with controls 
4 Values ≥200 IU/ml counted as 200 



























































































































































































































8.1.5 Numbers of functional C4A and C4B genes in rhinosinusi-
tis patients
Complement C4 function is crucial for one of the strongest innate im-
munity defense mechanisms, the complement system. Therefore, it was 
studied if missing C4A or C4B genes could affect the sinonasal disease 
susceptibility in females or males. The frequencies of C4A and C4B defi-
ciencies (a lack of at least one C4 gene) in patients and controls are shown 
in Table 10a and 10b.
An increased number of C4A deficiencies was seen in females with sCRS 
as compared with female controls (36 % vs. 17%, p=0.048). In males, this 
was not significant due to smaller groups (33% vs. 14% p=0.13). Total 
C4A deficiency was more common in males with sCRS as compared with 
male controls (13% vs 0%, p=0.052), but not significant in females (5% 
vs. 2%,  p=0.096). No differences in partial or total C4A deficiencies were 
seen between SNO or ARS patients and controls.
An increased number of C4B deficiencies in female SNO patients as com-
pared to female controls (62% vs. 38%; p=0.001) was found. No such dif-
ference was seen in male SNO patients (41% vs. 47% in controls). C4B de-
ficiencies in female SNO patients were also more common than in male 
SNO patients (p=0.005). The number of total C4B deficiencies was also 
high in female SNO patients (18%, controls 9%), but the difference was 
not significant (p=0.09).
When divided by clinical diagnosis, females with CRSwNP had a signif-
icantly higher incidence of C4B deficiency (74%) than female controls 
(38%, p<0.001). A complete C4B deficiency (two C4B null alleles) was 
found in 37% (7/19) of female patients with CRSwNP. This was also sig-
nificantly higher than in controls (9%; p=0.003). Significance between 
female and male CRSwNP patients was p=0.001 for partial and p<0.0001 
for total deficiency. The high incidence of C4B deficiency was found 
in CRSsNP patients (56/93=60%, p=0.003) as compared with controls 
(61/150=41%) (p=0.003). When divided by sex, C4B deficiencies had the 
same incidence in females (60%; n=63) and males (60%; n=30), but the 
difference to gender matched controls (38% F, 47% M) was only signifi-
cant in females (p=0.005 F, p=0.26 M). 
In female patients coming to sinonasal operations the likelihood of hav-
ing C4B deficiencies was higher than in female controls, OR 2.75 (95% 
CI 1.48-4.91) p=0.001. In female CRSsNP patients compared with female 
controls, OR for C4B deficiency was 2.52 (95% CI 1.26-5.06) p=0.006.  In 
female CRSwNP patients compared with female controls, OR for C4B de-
RESULTS
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ficiency was 4.64 (95% CI 1.41-17.6) p=0.005 and for total C4B deficiency 
5.96 (95% CI 1.55-21.7) p=0.004. 
Male patients with CRSwNP had the lowest incidence (11%) of C4B de-
ficiency of all male or female patient groups or controls and none had 
complete C4B deficiency. This difference was highly significant (p=0.002 
to male controls, p=0.0003 to other male SNO patients).
Since the male control group was relatively small, the analyses were re-
peated with a larger control group by including gender- and age-matched 
healthy controls from blood donors in study I with available data. The 
prevalence of C4B deficiency was 37% in 134 female controls and 45% 
in 64 male controls. The prevalence of total C4B deficiency in female and 
male controls was 9% and 13%, respectively. Statistical results remained 
essentially unchanged (data not shown). 
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Table 10a and 10b. Frequencies of C4 deficiencies in female (A) and male 
(B) patients in different clinical disease groups as compared to controls. 
I=patients from study I, II=patients from study II. 
10a. Females
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS 
= severe chronic rhinosinusitis, ARS = acute/intermittent (presumed bacterial) rhinosinusitis
C4 deficiencies n (% within group) Chi-square C and Fisher’s exact test F when appropriate, 1 p=0.023, 
2 p=0.019, 3 p=0.003
10b. Males 
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal 
polyposis, CRSwNP = chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS 
= severe chronic rhinosinusitis, ARS = acute/intermittent (presumed bacterial) rhinosinusitis
C4 deficiencies n (% within group) Chi-square C and Fisher’s exact test F when appropriate, 1 p=0.002
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Table 10. Frequencies of C4 deficiencies in female (A) and male (B) patients in 
different clinical disease groups as compared to controls. I=patients from study 
I, II=patients from stu  II.  
A. Females 
 
























  Controls   
C4 gene 
numbers 








C4A<2 14 (15) 8 (13) 3 (16) 3 (10) 
 
 
12 (36)  4 (10)  18 (17)  0.051C 
C4A=0 
 
1 (1) 0 (0) 0 (0) 1 (10)  3 (10)  2 (5)  2 (2)  0.057F 
C4B<2 58 (62) 
 
38 (60)1 14 (74)2 6 (55)  15 (45)  18 (46)  38 (38)  0.019C  
C4B=0 17 (18) 
 
8 (13) 7 (37)3 2 (18)  1 (3)  2 (5)  9 (9)  0.008F 
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
C4 deficiencies n (% within group) Chi-squareC and Fisher’s exact test F when appropriate, 10.023, 20.019, 30.003 
 
B. Males  
 








































C4A<2 15 (16) 3 (10) 5 (19) 7 (20) 
 
 
5 (33)  0  7 (14)  0.253F 
C4A=0 
 
1 (1) 0 (0) 1 (4) 0 (0)  2 (13)  0  0 (0)  0.02F 
C4B<2 37 (41) 
 
18 (60) 3 (11)1 16 (46)  8 (53)  6 (55)  23 (47)  0.009C 
C4B=0 4 (4) 
 
1 (3) 0 (0) 3 (8)  2 (13)  0  6 (12)  0.288F 
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
C4 deficiencies n (% within group) Chi-squareC and Fisher’s exact testF when appropriate, 1p=0.002  
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Table . Frequencies of C4 d ficiencies in female (A) and male (B) p tients in 
different clinical disease groups as compared to controls. I=patients from study 
I, II=patients from study II.  
A. Females 
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C4 gene 
numbers 








C4A<2 14 (15) 8 (13) 3 (16) 3 (10) 
 
 
12 (36)  4 (10)  18 (17)  0.051C 
A=0 
 
1 1) 0 (0) 0 (0) 1 (10)  3 10   2 (5)  2 (2  0.057F 
<2 58 62  
 
38 (60)1 14 ( 4)2 6 (55)  15 (45)  18 (46)  38 (38)  0. 19C  
C4B=0 17 (18) 
 
8 (13) 7 (37)3 2 (18)  1 (3)  2 (5) 9 (9)  0.008F 
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal p lyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
C4 deficiencies n (% within group) Chi-squareC and Fisher’s exact test F when appropriate, 10.023, 20.019, 30.003 
 
B. Males  
 








































C4A<2 15 (16) 3 (10) 5 (19) 7 (20) 
 
 
5 (33)  0  7 (14)  0.253F 
C4A=0 
 
1 (1) 0 (0) 1 (4) 0 (0)  2 (13)  0  0 (0)  0.02F 
C4B<2 37 (41) 
 
18 (60) 3 (11)1 16 (46)  8 (53)  6 (55)  23 (47)  0.009C 
C4B=0 4 (4) 
 
1 (3) 0 (0) 3 (8)  2 (13)  0  6 (12)  0.288F 
a All = all patients coming to sinonasal operation, CRSsNP  = chronic rhinosinusitis without nasal polyposis, CRSwNP = 
chronic rhinosinusitis with nasal polyposis, NPO = nasal polyposis only, sCRS = severe chronic rhinosinusitis, ARS = 
acute/intermittent (presumed bacterial) rhinosinusitis 
C4 d ficiencies n (% within group) Chi-squareC and Fisher’s exact testF when appropriate, 1p=0.002  
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8.2 Clinical and laboratory findings in pediatric patients 
with tonsillar diseases
8.2.1 Clinical observations in pediatric patients
Tonsillectomies are among the most frequent pediatric operations. Sex 
differences are also seen in the incidence and clinical manifestations of 
tonsillar diseases that are most common before adulthood. In this study 
factors influencing the susceptibility to tonsillar diseases and conse-
quences of previous adenoid surgery to the development of allergies later 
on were investigated. 
For these studies, we recruited 213 children (aged 2-16.9 years), coming 
to scheduled tonsillectomy. The median age of the patients at the time of 
tonsillectomy was 7.6 years. The indication for tonsillectomy was tonsil-
lar hypertrophy in 89%, recurrent tonsillitis in 27% and chronic tonsil-
litis in 26% of children. There were, on the average, 1.4 indications per 
operation. The primary indication (study IV) was tonsillar hypertrophy 
in 60%, recurrent tonsillitis in 20% and chronic tonsillitis in 20% of the 
children. The indication for tonsillectomy was strongly age-dependent. 
In children under 7 years of age, tonsillar hypertrophy was the most com-
mon (80%) primary operation indication, recurrent tonsillitis (8%) and 
chronic tonsillitis (10%) were less common. In children over 7 years of 
age tonsillar hypertrophy (40%) was still the main primary indication 
followed by recurrent tonsillitis (31%) and chronic tonsillitis (29%). No 
differences were found in the profiles of observed microbial flora (group 
A, B, C and G betahemolytic streptococci, Staphylococcus aureus, yeasts) 
in the tonsils of children under or over 7 years of age (data not shown). 
Table 11 shows clinical data of tonsillectomized children divided by age 
and sex. Snoring (p=0.002) and sleep apnea (p=0.009) were more com-
mon in boys than girls over 7 years of age.
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Table 11.  Main clinical characteristics between girls and boys of different 
age groups coming to tonsillectomy1. Statistically significant results bolded.
1 Results are shown as n (%)
2 Mann-Whitney U test
3 Chi-square test
4 URTI= Upper respiratory tract infections 
5 OME= Otitis media with effusion
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and sleep apnea (p=0.009) were more common in boys than girls over 7 years of age. 
 
Table 11.  Main clinical characteristics between girls and boys of different age 


























Number of patients (%) 98 44 (45) 54 (55)  
 
115 64 (56) 51 (44) 
 
Age median  4.5 4.4 4.6 0.9882 
 
11.7 12.7 10.7 0.0042 
Recurrent URTI4 39 (40) 17 (39) 22 (41) >0.9993 
 
64 (55) 36 (55) 28 (55) >0.9993 
Recurrent OME5 90 (92) 40 (91) 50 (93) >0.9993 
 
83 (72) 42 (65) 41 (80) 0.0963 
Recurrent sinusitis 10 (10) 6 (14) 4 (7) 0.3373 
 
37 (32) 18 (28) 19 (37) 0.3213 
Chronic rhinitis 36 (37) 15 (34) 21 (39) 0.6773 
 
33 (28) 15 (23) 18 (35) 0.2133 
Smoking at home 34 (35) 12 (27) 22 (41) 0.2033 
 
38 (33) 20 (31) 18 (35) 0.6933 
Previous adenoidectomy 43 (44) 15 (34) 28 (52) 0.1023 
 
57 (49) 29 (45) 28 (55) 0.3513 
Snoring 93 (95) 40 (91) 53 (98) 0.1703 
 
80 (69) 37 (57) 43 (84) 0.0023 
Sleep apnea 47 (48) 21 (48) 26 (48) >0.9993 
 
23 (20) 7 (11) 16 (31) 0.0093 
Chronic tonsillitis 10 (10) 3 (7) 7 (13) 0.5043 
 
46 (40) 30 (46) 16 (31) 0.1253 
Recurrent tonsillitis 13 (13) 6 (14) 7 (13) >0.9993 
 
45 (39) 29 (45) 16 (31) 0.1783 
Tonsillar hyperplasia 95 (97) 43 (98) 52 (96) >0.9993 
 
95 (82) 51 (78) 44 (86) 0.4563 
1 Results are shown as n (%) 
2 Mann-Whitney U test 
3 Chi-square test 
4 URTI= Upper respiratory tract infections  










8.2.2 Allergic diseases and previous adenoidectomy in tonsil-
lectomy patients
Adenotonsillar tissue belongs to the upper respiratory tract immune sys-
tem. It has an important role in the development of allergic sensitization, 
since respiratory and food allergens have to pass the Waldeyer’s ring to 
enter the body. In this work, the aim was to explore the role of allergy as 
a comorbid condition for adenotonsillectomy. The other point of inter-
est was to see if previously performed adenoidectomy would predispose 
to the development of allergic diseases or IgE-mediated sensitization to 
respiratory allergens.
Table 12 shows clinical characteristics in tonsillectomy patients divided 
into two groups according to preceding adenoidectomy (n=100) or the 
lack of it (n=113). The presence of specific serum IgE for common Finnish 
respiratory allergens was screened from the sera of all patients. The pa-
tient groups were compared with each other. Patients over 7 years of age 
(n=155) were also compared to a group of randomly selected school chil-
dren (n=155) of the same age. 
The results showed that recurrent otitis media (p<0.001), sinusitis 
(p=0.001), recurrent sinusitis (p=0.007) and rhinitis (p=0.011) were more 
common in the adenoidectomized children. 
Comparisons of the prevalence of allergy, asthma and the presence of 
allergen-specific IgE in different age groups according to previous ad-
enoidectomy are shown in Figure 6 and different clinical allergic diseases 
divided by age and sex in Figure 7. In children under the age of seven, any 
allergy (p=0.007), non-antibiotic allergy diagnosed by a doctor (p=0.015) 
and asthma (p=0.015) were more commonly seen if adenoidectomy had 
been done previously. Between ages 7 and 11 neither allergy nor asthma 
was associated with previous adenoidectomy. In children between 12 
and 17 years of age, only antibiotic allergy was more common if ade-
noidectomy had been done previously. In children under 7 years of age, 
doctor-diagnosed non-antibiotic allergy was significantly associated with 
reported recurrent upper respiratory tract infections OR 3.7 (95% CI 1.0-
13.6) p=0.046 and previous adenoidectomy OR 4.8 (95%CI 1.2-19.3) p= 
0.027. Previous adenoidectomy did not associate with the appearance of 
respiratory allergen-specific IgE later in life.
Of the 175 patients without a diagnosis of allergy to respiratory allergens, 
17 (10%) had specific IgE against at least one of the tested allergens and 
8 (5%) were multisensitized. Out of 24 asthmatic patients, 17 (71%) had 
been diagnosed with allergy: 16 to respiratory allergens, six to foods and 
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Table 12. Clinical characteristics of pediatric patients coming to tonsillec-
tomy (study III) divided into groups by previous adenoidectomy. Statistically 
significant results bolded. With permission from Rhinology.
1 Years 
2 Considered by guardian
3 >3 episodes of otitis/sinusitis verified by doctor
4 p-values between adenoidectomy+ and adenoidectomy- groups
5 Mann-Whitney U test
6 Chi-square test 
URTI= Upper respiratory tract infections
OME= Otitis media with effusion
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Table 12. Clinical r cteristics of pediatric patients coming to tonsillectomy 




































































172 (81) 82 (82) 90 (80) 0.664
6
 
Smoking at home 
 





78 (37) 36 (36) 42 (37) 0.859
6
 
1 Years  
2 Considered by guardian 
3 >3 episodes of otitis/sinusitis verified by doctor 
4 p-values between adenoidectomy+ and adenoidectomy- groups 
5 Mann-Whitney U test 
6 Chi-square test  
URTI= U per respiratory tract infections 
OME= Otitis media with effusion
two to antibiotics. Specific IgE was found in 13 (54%) of asthmatics and 
11 (45%) of them were multisensitized. Twelve (75%) of 16 asthmatics 
previously diagnosed with allergy to respiratory allergens had specific 
IgE against the tested respiratory allergens, 11 (69%) against several of 
them. 
In female patients under 7 years of age, specific IgE to respiratory aller-
gens was often seen (20% vs. 7 % in male patients; p=0.058) (Figure 8). 
In tonsillectomized boys over the age of 7, specific IgE (p=0.040), doctor-
diagnosed allergy (p=0.014), allergy to dusts (p=0.004) and doctor-diag-
nosed non-antibiotic allergy (p=0.015) were found more often than in 
girls (Figures 7 and 8). Although snoring and sleep apnea acknowledged 
by parents was more common in boys over 7 years than in girls of the 
same age, no association with allergy was found. Food and antibiotic al-
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Figure 6. The prevalence of doctor-diagnosed allergy and asthma from ques-
tionnaire analysis and serum specific IgE to respiratory allergens in pediatric 
patients coming to tonsillectomy (Study III) divided by age and the presence 
or absence of previous adenoidectomy. Children with previous adenoidec-
tomy present with more doctor-diagnosed allergy and asthma but not with 
more IgE specific for common respiratory allergens than children with no 
previous adenoidectomy. P-values for comparisons were obtained using the 
Chi-square test. 
RESULTS
lergy was equally common in girls and boys. Bronchial asthma was mar-
ginally more common in boys older than seven than in similarily-aged 
girls 14% vs. 5% (p=0.105) (Figure 7).
 
In control children, no statistical difference was seen in specific IgE to 
respiratory allergens between females and males. When the data from all 
children were pooled, males had significantly more often allergen-spe-
cific IgE than females (p=0.036 in children >7 years, p=0.035 in children 
































p = 0.014 p = 0.004 p = 0.015
Female
Male
Figure 7. History of doctor-diagnosed allergy and asthma in girls and boys 
who came to tonsillectomy, presented in age groups. Boys older than 7 years 
have more doctor-diagnosed allergy, allergy to dusts and doctor-diagnosed 
non-antibiotic allergy. P-values for comparisons were obtained using the 
Chi-square test.
Figure 8. Presence of specific serum IgE against common inhalant allergens 
in tonsillectomy patients and controls, in different age groups. P-values for 
comparisons of female and male groups in each age group were obtained 
using the Chi-square test.
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8.2.3 Tonsillar streptococci and binding of complement regula-
tors FH and C4BP
Tonsils are known to harbor potential pathogens even without symptoms 
of infection. The causes for bacterial persistence and virulence in the ton-
sils are not well known. Group A streptococci can escape opsonophago-
cytosis by binding soluble complement inhibitors. Thus it was of interest 
to find out whether tonsillar streptococcal strains isolated from patients 
would be able to use host complement regulatory factors FH and C4BP 
and how this ability would correlate with their pathogenicity and with the 
studied clinical parameters of the patients.
Bacteriological cultures were performed from the removed tonsils 
(n=403). Streptococci were isolated from 21% of the tonsillectomy pa-
tients. Thus, altogether 79 streptococcal strains were obtained from 403 
tonsils removed. Of these, 56 were GAS, four group B streptococci (GBS), 
seven group C streptococci (GCS) and 12 group G streptococci (GGS). 
Subsequently, strains from two tonsils of a single patient were treated as 
one strain. To study the possible immune evasion mechanisms of the iso-
lated bacteria, 26 GAS, two GBS, two GCS and four GGS strains were 
compared for their ability to bind FH and C4BP. No or only weak FH or 
C4BP binding ability was seen in GBS, GCS or GGS strains. On the other 
hand, 6 of the GAS strains were found to bind FH and/or C4BP above the 
threshold levels. Subsequently, T and emm types of the GAS strains were 
determined. Two GAS of M4 serotype could bind both FH and C4BP. 
The clinical course of tonsillar disease and operation indication did not 
correlate with streptococcal strains nor complement regulator binding, 
or the T or emm serotype of GAS. 
Since binding of complement regulators has been suggested to be impor-
tant for bacterial virulence, the ability of tonsillar strains to bind C4BP 
and FH was compared with 10 GAS strains isolated from bacteremia pa-
tients. For this analysis 5 M1 and 5 strains representing other serotypes 
were selected. Of the bacteremia strains two could bind FH and three 
C4BP (Figure 9). M1 strains were not more efficient in complement reg-
ulator binding than the other strains. Tonsillar strains bound more C4BP, 
and the bacteremia strains more FH. Only marginal statistically nonsig-
nificant correlation of the T or M types of the bacteria with complement 
regulator binding was observed.
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Figure 9. Direct binding of 125I labeled complement regulators FH and C4BP 
by GAS strains isolated from tonsils and blood (Study IV). Tonsillar strains 
bound more C4BP, and the bacteremia (sepsis) strains more FH. Only a par-
tial correlation of the T or M types of the bacteria with complement regula-
tor binding was observed. With permission from Elsevier.
76
8.2.4 Human rhinovirus/enterovirus (HRV/HEV) in pediatric 
tonsillar disease
Human rhinovirus is the most common causative agent for respiratory 
infections and an important cause of asthma exacerbations. It has been 
earlier found in all other parts of the respiratory tract except the palatine 
tonsils. To find out if rhinovirus can be detected in tonsillar tissue, we 
took tonsillar samples from 33 consecutive tonsillectomies at the Clinic of 
Otolaryngology, Head and Neck Surgery of Helsinki University Hospital, 
between February and March 2003, outside the primary rhinovirus sea-
sons. Children did not have acute respiratory symptoms at the time of 
operation. 
A positive in situ hybridization result for HRV was observed in 20 (62%) 
of the 33 specimens. No association was found between a positive HRV 
result by the in situ hydridization (HRV-ISH) test and patient demo-
graphics, history of respiratory diseases, tonsillectomy indication, or 
positive bacterial or yeast culture from the tonsils. The HRV-ISH signal 
was localized to epithelial and lymphoid cells in the tonsils (Figure 10). 
For further verification of the findings 5 HRV-ISH negative and 5 positive 
samples were investigated with a hanging drop-nested PCR method and 
conventional PCR hybridization assay (PCR-HYB) in a separate labora-
tory. With the more sensitive nested PCR picornavirus RNA was detected 
in 9 (90%) of 10 samples. One HRV-ISH negative sample was positive 
by both PCR methods and only one was negative by all methods. Thus, 






































































































































































































































































Females are reported to have more numerous, but less severe infections 
of the upper respiratory tract and males fewer, but more serious (Falagas 
et al. 2008). Female patients also report more frequent, numerous and 
intense other bodily symptoms than males (Bensing et al. 1993). Males 
after puberty, however, tend to underreport or deny respiratory symp-
toms, and forget their previous illnesses (Wieringa et al. 1999). As pu-
berty seems to be a crucial time point, some of these differences may be 
explained by sex-hormones, some by behavioral pressures. 
The differences in attitudes towards illnesses may be connected to the de-
velopment of different forms of sinonasal diseases. Male behavior tends 
to create delays in seeking treatment, and this may predispose to compli-
cations. Female behavior may predispose to repetitive treatments for less 
severe symptoms. Our results about the history of more frequent mucosal 
infections in females (Figure 5) are in line with previous data, but can 
be affected by this reporting bias from both sexes (Stalman et al. 2001; 
Shashy et al. 2004; Falagas et al. 2008). 
As an objective proof that different phenotypes in female and male pa-
tients do exist, we utilized clinical diagnostic grouping (Figure 5) and 
CT scoring (Table 8a and 8b), which both confirmed that males had 
more mucosal changes in their noses and sinuses. Similar observations 
have been made in other studies (Chen et al. 2003; Baumann et al. 2007; 
Busaba et al. 2008a; Busaba et al. 2008b). Both female and male patients 
with polyposis coming to operation were older than the ones with no 
polyposis. This suggests that polyposis takes a longer time to develop and 
that sinonasal polyp disease may just be complicated form of chronic R. 
This spectrum of disease is also suggested by the latest position paper of 
R and nasal polyps (Fokkens et al. 2007). However, our results in patients 
undergoing sinonasal operations suggest that there are considerable dif-
ferences between female and male genotypes, even when the patients 
share the same phenotype CRSwNP. In females with CRSwNP, C4B defi-
ciencies were very common, but in males very uncommon. The underly-
ing cause for sinonasal polyposis may thus be completely different and 
independent from the C4B deficiencies found. 
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Clinically, the results suggest that the physicians’ approach to female and 
male sinusitis patients should be different. Mucosal findings in endos-
copy and CT scans tend to be more prominent in male patients and asso-
ciate with sinonasal polyposis. Sinonasal polyposis is a chronic mucosal 
disorder, and the primary treatment for it is not operative. Operations 
should be reserved for patients who do not sufficiently benefit from lo-
cal or systemic steroids, leading to frequent recurrencies of NP. Sadly, 
operation does not necessarily guarantee better outcome. However, it is 
possible that in recurrent and chronic R males are not motivated enough 
to take the prescribed medications and therefore may be in risk for infec-
tious complications. In females who have a lower threshold for physician 
contacts and who have a lower Lund-Mackay score in CT as a sign of less 
pronounced mucosal reaction, a decision to operate would call for careful 
diagnostics and sufficient follow-up with conservative treatment. Both in 
females and males diagnostic imaging, if conservative treatment fails, is 
elementary. In females, the goal would be to confirm that the diagnosis is 
truly a R and not just local swelling unresponsive to antibiotics but caus-
ing pressure symptoms. In males, the main indication for imaging would 
be to rule out complicated and/or polypoid disease. 
9.1.2 Complement activation
Interestingly, acute R patients had very high levels of C3, C4 and CH50 
as compared with controls. No difference was seen between females and 
males. This indicates the involvement of complement in inflammation 
in acute bacterial rhinosinusitis since C3 and C4 behave as acute phase 
proteins. This further suggests that complement activation could be an 
important part of the immunological reaction in acute R. 
Previously, a higher level of complement factor C4 in male patients with 
CRS when compared to females has been shown (Ogunleye et al. 2001). 
This finding was confirmed in this study. The same was found in C3 lev-
els. The higher C4 levels in all male SNO patient groups with no differ-
ences in the amounts of C4 gene deficiencies when compared to controls 
and female SNO patients suggests an increased complement turnover in 
male sinonasal disease leading to operation. 
9.1.3 Complement C4 deficiencies 
In clinical patient groups, the low number of C4A or C4B genes was not 
associated with the circulating C4 levels. Serum C4 protein concentration 
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reflects only partially the C4B copy number as these patients usually have 
more than 2 C4A genes because of gene conversions (Yang et al. 2003). 
Only if the total number of C4 genes was 2, we could see an effect on se-
rum C4 level (data not shown). This suggests that more important than 
total C4 levels in serum is whether the levels of C4A or C4B isotypes are 
disproportionately low.  Due to the poor availability of isotype-specific 
antibodies that would enable the measurement of C4A and C4B sepa-
rately, we only measured the levels of total C4 protein.
It is known that C4A binds more avidly to free amino groups on pro-
tein antigens and C4B to hydroxyl groups on carbohydrate antigens. The 
predominant function of C4A is opsonization and immune complex 
clearance, and of C4B killing of the pathogens by promoting lysis and 
neutralization (Guerra-Junior et al. 2008). In clinical studies, C4B de-
ficiencies have been associated most often with chronic and recurrent 
viral infections (Pasta et al. 2004; Seppänen et al. 2006).  In our study 
I, C4A deficiencies were associated with severe chronic and recurrent R 
(Seppänen et al. 2006). 
C4B deficiencies were associated with chronic and recurrent sinus infec-
tions without nasal polyposis (60% CRSsNP patients vs 41% controls, 
p=0.003) especially in female patients. The highest numbers of total (37%) 
and partial (74%) C4B deficiencies were seen at females with CRSwNP. 
In females and males, partial C4B deficiencies were in the same level in 
the CRSsNP group (F 60%, M 60%), but possibly due to the small sizes of 
the male patient and control groups this was significant only in females. 
Males with CRSwNP had the lowest level of C4B deficiencies (0% total, 
11% partial) of all patient groups and controls. 
It seems that genetic deficiencies of C4A and C4B genes are associated 
with different forms of sinonasal disease. C4A deficiency is associated 
with severe chronic sinonasal disease. C4B deficiency is associated with 
CRSsNP in all patients. In female patients with CRSwNP C4B deficiency 
is also associated with a greater risk for disease. In males, the same de-
ficiency may even be protective, or our findings in men were caused by 
chance due to the small size of the male control group. This suggests that 
the effect of C4B deficiencies to CRSsNP in females and males is similar, 
but to CRSwNP different. However, no differences between females and 
males or between patients and controls in NPO group were seen in C4A 
or C4B deficiencies suggesting that nasal polyposis without sinus infec-
tions is not associated with this deficiency. 
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9.1.4 Immunoglobulin levels 
An IgG subclass level below 2 standard deviations from the mean defines 
low subclass level. However, due to the lack of published reference mate-
rials and universally accepted methods to measure subclasses there is also 
a lack of universally accepted reference values (Buckley 2002). Clinical 
consequences of low IgG subclass levels, in the absence of known immu-
nodeficiency, are thus not clear. 
Only one patient suffering from a severe primary antibody deficiency 
was found from our patients coming for sinonasal operation. Different Ig 
classes and IgG subclasses, defined by their heavy chains, elicit different 
effector functions. IgG2 and IgG1 are important against purulent extra-
cellular infections, while IgG1 and IgG3 are complement-fixing antibod-
ies that neutralize viruses and further elicit complement-mediated killing 
of microbes (Avery et al. 2008). Ig isotype-switching is a dynamic proc-
ess during the immune response, the mechanisms of which in humans 
are being increasingly understood (Honjo et al. 2004; Avery et al. 2008). 
Low IgG subclass levels are mainly caused by immune dysregulation as-
sociated with a disturbed cytokine balance, leading to subtly impaired 
Ig isotype-switching. In humans, Th1/Th2/iTreg/Th17 –polarization (in-
volving among others IFNγ, IL-4, IL-17, IL-21, and IL-27) regulates the 
relative efficacy of isotype-switch to IgG3, IgG1, IgG2, IgA and/or IgE 
(Avery et al. 2008). Lower, but physiological levels of IgG1 and IgG3 with-
out high levels of IgA and IgG2 in ARS patients may reflect consumption 
of these Th1-type Igs. The results both in females and males either sug-
gest subtly impaired Th1 responses and IgG1 and IgG3 production, and/
or Th2-dominant responses with a relative overproduction of IgA, IgG2 
and specific IgE. Normal, even raised, IgG2 and IgA levels in our patients 
suggest that the great majority of patients admitted to sinus surgery have 
adequate humoral immunity against common extracellular bacteria (e.g. 
S. pneumoniae and H. influenzae) causing purulent infections in the si-
nuses (Buckley 2002; Bonilla et al. 2005; Avery et al. 2008). 
The minor differences in the levels of IgA and IgM between different di-
agnosis groups of SNO patients are too low to reflect major patophysi-
ological differences between these groups.
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9.1.5 Allergic diseases 
In SNO patient groups, allergic symptoms were commonly reported (fe-
males 58-75%, males 36-75%). In the study by Pallasaho, in Finnish young 
adults the prevalence of allergic rhinitis or conjunctivitis was 21-28% in 
females and 21-27% in males; atopic dermatitis 20-25% in females and 
13-17% in males; asthma 4-7% in females and 3-10% in males (Pallasaho 
et al. 2006). Consequently, the prevalence of allergic symptoms and the 
difference between females and males coming to operation for sinonasal 
diseases are not different from that of normal population. In ARS pa-
tients, allergic symptoms were not commonly reported by females (15%), 
as compared with males (36%). This may be associated with the age dif-
ference (median age 46 years F, 31 years M).
Bronchial asthma was commonly reported by all patients with severe 
chronic sinusitis (female 55%, male 60%) and in all operated sinusitis 
patients with polyposis (female CRSwNP 65%, NPO 50%; male CRSwNP 
46%, NPO 53%). The reported prevalence of doctor-diagnosed bron-
chial asthma in the Helsinki area is 7.0% in females and 5.1% in males 
(Pallasaho et al. 2002). This association of hyperinflammatory nasal 
disease and hyperreactivity in LRT has also been seen in earlier studies 
(Fokkens et al. 2007). 
Specific IgE to respiratory allergens was found more commonly in male 
(42%) than female (28%) SNO patients. The female figure of specific 
IgE is in concordance with a previous report of Finnish females (25%) 
(Pekkarinen et al. 2007). With another test method, skin prick testing, al-
lergic sensitization was found in 50% of adult males and 44% of adult fe-
males (Pallasaho et al. 2006).  Our results suggest that respiratory allergy 




9.2. Pediatric tonsillar diseases
9.2.1 Respiratory infections, adenoidectomy and allergy 
Adenoid tissue is associated with both the development of allergy and 
resistance to respiratory infections (Brodsky et al. 1993; Lagging et al. 
1998). Viral upper respiratory infections, especially those caused by rhi-
novirus, induce and exacerbate allergic symptoms and bronchial asthma 
(Custovic et al. 2005; Heymann et al. 2005; Wark et al. 2005). Conflicting 
reports about the association of previous adenoidectomy and later devel-
opment of allergy have been published (Kvaerner et al. 2002; Custovic et 
al. 2005; Heymann et al. 2005; Wark et al. 2005). 
Based on our study, it could be proposed that hypersensitivity disorders 
and URTI commonly affect the same children. When compared with 
children with no previous adenoidectomy, doctor-diagnosed allergy and 
asthma were significantly more common in children who had undergone 
adenoidectomy and were prone to upper respiratory infections, especially 
in children under 7 years of age.  The most interesting finding of study III 
was the difference between symptomatic hypersensitivity and bronchial 
asthma when compared with the presence of specific IgE to common in-
halant allergens in the serum, especially in children under 7 years of age. 
These associations of adenoidectomy, allergy, recurrent infections and 
asthma in children under 7 years have been recently also confirmed by 
others (Mattila et al. 2009). 
An interesting six-fold increase (from 7% to 43%) of specific serum IgE 
to common inhalant allergens was seen in boys from under 7 years of age 
to over 7 years of age. In females of the same age groups the increase was 
only from 20% to 25%. Similarly, in history of doctor-diagnosed allergy 
to dusts a 5.5-fold (from 7 to 39%) and in doctor-diagnosed nonantibiot-
ic allergy a 3-fold (from 13% to 41%) increase was seen in boys, but not in 
girls (from 12 to 16% and 16 to 20% respectively) when children younger 
than 7 years were compared with school children. In antibiotic allergy, a 
two-fold increase was seen in both girls and boys, but no differences in 
food allergy or bronchial asthma were found. These populations are high-
ly selected by their tonsillectomy indications, which is most commonly 
tonsillar hyperplasia in pre-school children and tonsillar infections in 
school children. This was not a follow-up study. Therefore conclusions 
about the significance of this phenomenon cannot be drawn.
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9.2.2 Complement evasion by GAS in tonsils 
Innate immune responses are raised rapidly against microbes and materi-
al from non-viable self-cells, acting even in the most primitive organisms. 
Thus it would be beneficial for a pathogen to be able to invade host tissue 
without innate immunity recognition and with less risk for defensive ac-
tions from innate and adaptive immunity. 
A very effective weapon of target destruction and opsonization is the 
complement system, which functions both in innate and adaptive im-
munity. Due to its aggressive self-perpetuating nature it has to be tightly 
controlled by regulatory membrane-bound and soluble factors to avoid 
unnecessary damage to host cells. These factors limit C activation in the 
vicinity of host cells. 
Human C response is lured by several pathogens that acquire soluble C 
regulatory factors from the host. Therefore, in this work the ability of a 
common tonsillar pathogen, GAS, to bind C regulatory factors FH and 
C4BP was studied in vitro. Somewhat surprisingly, the binding ability 
was relatively weak and less commonly found in the bacteria than ex-
pected. Furthermore, the occurrence of bacteria with complement regu-
lator binding ability did not associate with any characteristics of tonsillar 
disease. 
When the complement regulator binding strains from tonsillitis patients 
were tested against strains derived from the blood of septicemia patients, 
only a very marginal difference in binding of FH and C4BP was seen. 
When studied if the binding was associated with some specific GAS se-
rotypes, the regulator binding strains were found to be mostly of sero-
type M1, M4 or M28.  The binding varied also within the same serotype. 
M28 was the most common serotype isolated, as also seen in nationwide 
survey for the same year (Siljander et al. 2006). In earlier studies, C4BP 
binding has been seen to some, but not all M4, M6, M8, M11, M18, M28 
and M78 serotypes (Perez-Caballero et al. 2000).
These in vitro results suggest that the acquisition of host complement 
regulatory factors FH and C4BP is not the only virulence factor for GAS 
that enables it to cause clinical disease in humans. GAS phagocytosis re-
sistance is multifactorial and may not depend on the binding of soluble 
complement regulators FH and FHL-1 (Cunningham 2000). GAS has 
also other virulence factors that promote the entry to host cells and in-
crease phagocytosis resistance, which may have a more paramount effect 
on the tonsillar disease.
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9.2.3 Rhinoviruses in tonsils
Rhinovirus is the one of the most common acute respiratory pathogens, 
and it is responsible for most of the exacerbations of bronchial asthma. 
In patients with asthma allergen sensitization, high allergen exposure 
and viral infection were not independent risks for hospital admission 
for asthma exacerbation, but simultaneously raised the risk for asthma 
admission ninefold (Custovic et al. 2005). Study number V focused on 
rhinovirus and showed that during early spring HRV RNA is found also 
in tonsils. Earlier, HRV RNA has been found in all other parts of the res-
piratory tract. 
February-March is not the peak season for rhinovirus infections (Monto 
2002). During the same season, using the same ISH method, HRV detec-
tion rates similar to those found in tonsils have been found also in the 
adenoids (Rihkanen et al. 2004). Therefore, the frequency of the positive 
detection of HRV/HEV was not a surprise. Other methods used to con-
firm the primary findings were even more sensitive and revealed more 
positive results for HRV in tonsils.
The role of HRV/HEV in tonsillar pathology is unclear. It is not known, 
if tonsillar cells can be infected with HRV/HEV. Thus it cannot be said 
whether the presence of HRV/HEV in tonsils is just a remnant of previ-
ous infection, a sign of an early, yet subclinical new, or even a chronic in-
fection.  One reason for the high occurrence of rhinovirus in the adenoid 
and tonsillar tissues may be related to the immunological function of the 
human adenotonsillar (AT) tissue. AT is constantly sampling particles 
passing down the pharyngeal passages for immunological recognition 
and possibly as a template for antigen production. Therefore, it is natural 
that many potential respiratory pathogens end up in tonsillar tissue. Why 
the HRV-infected cells are not destroyed by innate and adaptive immune 
mechanisms is not known. Alternatively, the viruses could replicate for 
limited a time until they are destroyed. This would be concordant with 
the fact that T-lymphocytes from tonsillar tissue have been shown to re-
act to rhinovirus and create a Th1 type response with IFN-gamma and 
IL-2 production (Wimalasundera et al. 1997).
With the ISH method, HRV-RNA was located to epithelial and lymphoid 
cells. Rhinovirus RNA is taken into the cells mostly through ICAM-1 re-
ceptors. This cell surface glycoprotein is present on APCs, lymphocytes, 
eosinophils, mast cells, submucosal glands, airway smooth muscle cells, 
and epithelial cells. It also regulates leukocyte trafficking and accumula-
tion at sites of inflammation. Rhinovirus intake and replication leads to 
the upregulation of ICAM-1 receptors in epithelial cells (Paganelli et al. 
DISCUSSION
86
1998). Direct cellular injury caused by rhinovirus infections results in 
little cellular destruction in experimental infections (Skoner et al. 1995). 
We could not find any association with detected rhinoviruses and clinical 
tonsillectomy indications.  Rhinovirus infection induces a rapid increase 
in serum IgE levels without evidence of elevation in the antigen-specific 
IgE in allergic subjects (Skoner et al. 1995). The role of those high IgE lev-
els is unknown. A synergism between high specific antibody levels with 
allergic disease and natural virus infection has been suggested (Custovic 
et al. 2005). Atopic subjects and especially individuals with bronchial hy-
perreactivity have been recognized to be more susceptible to HRV infec-
tions and to more severe cold (Kelly et al. 2008). It is possible that tonsils 
act as a natural reservoir for HRV between acute exacerbations. Further 
research is needed to confirm the association of tonsillar rhinoviruses 
with allergic respiratory disease.
9.3 General discussion: limitations and findings of special 
interests in the study
In study number I, patients with severe chronic sinusitis were collected 
retrospectively. There may be a selection bias in the collection of this pa-
tient group. However, the inclusion and exclusion criteria applied were 
the same throughout the study. 
In the reporting of medical history, the patients’ opinions were trusted 
and not cross-checked from other sources. Differences between female 
and male behavior and reporting of their previous illnesses may be con-
founding factors especially when it comes to previous minor infections in 
adults. In children, the questionnaires were usually filled by the guardian 
and it may be possible that accuracy of the history given by the father was 
not the same as the one given by the mother (Pless et al. 1995). 
The control group of males was unfortunately small and, therefore, some 
of the possible differences may have not reached statistical significance. 
However, when all available healthy control subjects were pooled, in-
creasing the number of female controls to 134 and male controls to 64, 
the percentages of C4 deficiencies and the results remained essentially 
unchanged.
We did not ask the geographical origin of the patients. It is known that 
in different parts of Finland, the population selection has led to local en-
richment of disease genes (Salmela et al. 2008). However, the genetically 
most heterogeneous population in Finland is found in the Helsinki capi-




When studying the associations of clinical sinonasal or tonsillar disease 
and causative factors one confounding factor may be the difficulty to de-
termine the clinically most relevant indication to operate. Tonsillectomy 
patients had on average 1.4 diagnoses and also in R one diagnosis does 
not exclude others. The diagnosis of acute bacterial R in general practice 
is known to be difficult (Lindbaek et al. 2002). Recurrent R is especially 
difficult to determine, as it is uncommon to have radiological or other 
verification for acute episodes.
In R, new EPOS guidelines have stratified the different types of R for 
clinical use and research (Table 4) (Fokkens et al. 2007). The definition 
for research in the EPOS guidelines accepts that there is a spectrum of 
diseases in CRS, which includes a polypoid change in the sinuses and/or 
middle meatus, but excludes those with polypoid disease presenting in 
the nasal cavity to avoid overlap. Thus CRS with polyposis is considered 
a subgroup within CRS. Also, recurrent R has been dropped out from 
the CRS definitions in EPOS. Because of these major changes in guide-
lines the definitions used in these studies are not fully compliant with 
the current ones. When the patients for the present study were recruited, 
the EPOS guidelines did not yet exist. Therefore the American Academy 
of Otolaryngology-Head and Neck Surgery 1997 criteria were applied as 
the inclusion criteria (Lanza et al. 1997). However, it is known that the 
clinical diagnoses are not always as clear-cut as the criteria in guidelines. 
Overlap between patient groups may exist, and therefore too detailed pa-
tient classification must be judged with caution. 
We could show that patients fullfilling the criteria for severe chronic R 
had an increased number of C4A deficiencies. Impaired immune complex 
clearance as a consequence of C4A deficiencies after acute sinusitis epi-
sode may lead to the development of chronic disease. On the other hand, 
C4B deficiencies, which potentially impair the killing of encapsulated 
pathogens were associated with CRSsNP. This association was strongest 
in female patients, who report more recurrent sinonasal infections.
 
Most interestingly, females and males in the clinically similar group of 
recurrent or chronic R together with nasal polyposis (CRSwNP) had a 
very different number of C4B deficiencies. This would suggest that the 
pathogenesis of this disorder might be different in females and males. 
However, this needs to be confirmed in further studies. The determina-
tion of the number of C4A and C4B genes may help in clinical decision-
making. Patients with C4A deficiencies should be considered as being 
at risk for worse outcome and disease progression. Patients, especially 
females, with C4B deficiencies are at risk for recurrent sinus infections, 
but do not necessarily have the worst prognosis. We did not study direct 
activation of the different C pathways. As C seems to be upregulated in 
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sinonasal diseases, and different forms of disease are associated with dif-
ferent C deficiencies, it would be interesting to compare the activation of 
different C pathways in the different forms of sinonasal diseases.
We did not study the cause for the differences in serum Ig levels of pa-
tients. It is known that polymorphisms of several genes regulating TLR 
signalling and IL levels may result in differences in Ig subclass levels 
(Kimman et al. 2008). 
In tonsillar diseases, the clinical classification is even more difficult than 
in R, since no commonly accepted guidelines have been presented. Not 
uncommonly, a child has tonsillar hyperplasia simultaneously with re-
current or chronic tonsillitis, which together lead to the decision to op-
erate. In this study, all indications for the operations were recorded, but 
the primary indication was systematically determined: hyperplasia if no 
chronic or recurrent infections were noted, chronic tonsillitis, if not con-
nected with recurrent episodes of acute tonsillitis, and recurrent tonsil-
litis with recurrent episodes of acute exacerbations. In this way clear and 
non-overlapping diagnosis groups could be made at least for tonsillar in-
fections. Tonsillar hyperplasia is a common feature also in patients with 
tonsillar infections. Therefore, these patients were seen also in chronic 
and recurrent tonsillitis groups. GAS complement inhibitor binding or 
HRV detection were not associated with different tonsillar diseases or 
tonsillectomy indications.
It is important to realize that female and male patients not only have dif-
ferent frequency and forms of infectious respiratory diseases, but they 
also behave differently as a consequence of the disease. Females are more 
sensitive to symptoms and seek medical treatment more easily. Males 
tend to underreport, deny and forget symptoms.  These differences make 
it challenging to judge whether conservative treatment has been success-
ful or not and whether operation would be necessary. It is commonly 
acknowledged that a great deal of operations could be avoided with ef-
fective conservative treatments. There is great need for markers to aid 
clinical decision on operative treatment. 
The control subjects in both adult R and pediatric tonsillectomy studies 
were only collected for serological and gene studies and did not fill out 
questionnaires. Therefore, we can compare the incidence of symptoms 
of sinonasal, tonsillar or allergic diseases only between different patient 
groups and not with control groups. Interestingly, in the incidences of 
both allergic symptoms and specific IgE sensitization in children coming 
to tonsillectomy a suggestive sex-linked difference was seen. Although 
confounding factors are clear (for example, selected populations based on 
tonsillectomy diagnosis) this suggests that for sex-associated differences 
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should be taken into account in further pediatric studies on the develop-
ment of allergy.
Immunity plays a crucial role in infectious and inflammatory respiratory 
diseases. Usually it is not the infective agent itself, but the immunologi-
cal defense mechanisms it triggers that cause the patients’ symptoms. 
Different reaction types modulate the disease and are responsible for the 
variations in prognosis. For the most part, this appears to be the case also 
in the diseases studied in this thesis.   
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10 CONCLUSIONS       
  
On the basis of results obtained in this thesis, the following conclusions 
can be drawn. 
1. Sinonasal diseases in adult patients exhibit sexual dimorphism: females 
more commonly suffer from recurrent infections without polyposis while 
males develop sinonasal polyposis.
2. Complement system upregulation and possibly activation is an impor-
tant factor of acute rhinosinusitis in females and males. In males, com-
plement upregulation is also associated with sinonasal diseases leading 
to operations. The full role of complement in sinonasal diseases remains 
to be explored.
3. In females, complement C4B deficiency and low levels of IgG1 and 
IgG3 are associated with and may be risk factors for chronic or recurrent 
adult rhinosinusitis leading to sinonasal operations.
4. In children under 7 years of age, allergies and recurrent infections 
commonly affect the same individuals. Previously performed adenoidec-
tomy did not have an effect on specific IgE levels to respiratory allergens 
in children.
5. Binding of complement regulators FH and C4BP in vitro occurs only 
by occasional GAS strains isolated from tonsillar tissue or blood. Binding 
did not correlate with the form of tonsillar disease. 
6. HRV/HEV is commonly found within tonsils of children. HRV/HEV 







In the first part of this thesis the association of different forms of sino-
nasal diseases and plasma concentrations of C3, C4, immunoglobulins, 
immunoglobulin G subclasses, C4A and C4B gene numbers were studied 
in 287 adult patients and 150 sex-matched adult controls. Patients were 
well characterized and stratified into groups using strict clinical criteria 
and females and males were also studied as separate groups. 
Severe primary antibody antibody deficiencies were rare in patients com-
ing to sinonasal operations. Female patients had more recurrent sinusi-
tis and other mucosal infections and males had more nasal polyposis. 
Upregulation of complement activity was seen in acute rhinosinusitis pa-
tients (high levels of plasma C3, C4, and complement classical pathway 
activity CH50) and male patients coming to sinonasal operations (high 
levels of plasma C3 and C4). In females, total and partial C4B deficiencies 
and lower levels of IgG1 and IgG3 were associated with rhinosinusitis 
leading to sinonasal operations. C4A deficiencies were found to predis-
pose to severe chronic rhinosinusitis in females and males. In female pa-
tients with chronic or recurrent rhinosinusitis with nasal polyposis C4B 
deficiencies seem to predispose to the disease, but in males with a similar 
disease C4B deficiencies seem to be protective. This suggests a different 
pathophysiology between sexes in this form of sinonasal disease.
In the second part of this thesis work 213 children coming to elective 
tonsillectomy were studied and compared with 155 randomly selected 
school children. An association with recurrent upper respiratory tract 
infections and hypersensitivity disorders was seen especially in children 
under 7 years of age. However, this association was not seen in levels of 
specific IgE to respiratory allergens in the same age group. Both sympto-
matic respiratory allergy and specific IgE to respiratory allergens became 
more common in boys than girls over 7 years of age. 
We were able to show that although both rhinoviruses and bacterial path-
ogens were found in the tonsils, no association between their presence 
and clinical forms of tonsillar disease was seen. The ability of GAS to 
bind complement regulators FH and C4BP did not differ between strains 
causing tonsillar diseases or septicemia, suggesting that other virulence 
mechanisms of the bacteria are more important.
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12 TIIVISTELMÄ (FINNISH SUMMARY)   
  
Väitöstutkimuksen ensimmäisessä osassa selvitettiin nenän ja sivuon-
teloiden tulehdusten ja polyyppitaudin yhteyttä komplementin C3- ja 
C4-tasoihin, vasta-aineiden ja niiden alaluokkien plasmapitoisuuksiin ja 
C4A- ja C4B geenilukumääriin tutkimalla 287 aikuista potilasta ja 150 
aikuista kontrollihenkilöä. Potilaat jaettiin ryhmiin tiukkojen kliinisten 
kriteerien mukaan tutkien naiset ja miehet myös erillisinä ryhminään.
Vakavat vasta-ainepuutokset olivat harvinaisia sivuonteloleikkauksiin 
tulevilla potilailla. Naisilla oli yleisemmin toistuvia sivuontelontuleh-
duksia ja muita limakalvotulehduksia ja miehillä nenän polyyppitautia. 
Komplementin toiminnan lisääntymisen merkkejä oli havaittavissa äkil-
listä poskiontelontulehdusta sairastavilla potilailla (korkeat plasman C3, 
C4 ja komplementin klassisen tien aktivaation CH50 tasot) ja sivuontelo-
leikkaukseen tulevilla miehillä (korkeat plasman C3-, C4-tasot). Naisilla 
täydelliset ja osittaiset C4B-geenipuutokset ja matalat plasman IgG1- ja 
IgG2-tasot liittyivät leikkaukseen johtavaan sivuontelotautiin. C4A-
geenipuutokset altistivat sekä miehiä että naisia vaikeille sivuontelontu-
lehduksille. Kroonista tai toistuvaa sivuontelontulehdusta ja polyyppitau-
tia samanaikaisesti sairastavilla naispotilailla C4B-puutokset vaikuttivat 
altistavan sairaudelle, mutta samalla tavalla sairastavilla miespotilailla 
samalla puutoksella oli suojaava vaikutus. Tämä viittaa siihen, että tämä 
sivuontelotaudin muoto kehittyy eri tavalla naisilla ja miehillä.
Väitöstutkimuksen toisessa osassa tutkittiin 213 nielurisaleikkaukseen 
tulevaa lapsipotilasta verraten heitä 155 satunnaisesti valittuun koulu-
laislapseen. Toistuvien ylähengitystieinfektioiden ja yliherkkyysoireiden 
välillä havaittiin yhteys alle 7-vuotiailla lapsilla. Tätä yhteyttä ei kuiten-
kaan ollut havaittavissa seerumin allergia-vasta-ainetutkimuksessa. Sekä 
oireinen hengitystieallergia että spesifisten vasta-aineiden määrä seeru-
missa lisääntyivät kouluiässä pojilla tyttöjä enemmän. 
Tutkimuksessa pystyttiin osoittamaan, että vaikka sekä rinoviruksia että 
tautia aiheuttavia bakteereja on osoitettavissa nielurisoissa, niiden läsnä-
ololla ei ollut vaikutusta nielurisasairauden laatuun. Nielurisoista ja ve-
renmyrkytyspotilailta eristettyjen A-streptokokkien kyvyllä sitoa komple-
mentin säätelytekijöitä FH ja C4BP ei ollut vaikutusta näiden bakteerien 
aiheuttamien sairauksien kulkuun viitaten siihen, että muilla bakteerin 
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Tutkittavan potilaan kyselykaavake         




POSKIONTELOTULEHDUSTEN JA NENÄPOLYPOOSIN IMMUNOLOGISET 
TAUSTATEKIJÄT 
Sukupuoli      � nainen    � mies  Syntymävuosi: 19____           Ikä:____v 
Poissulkukriteerit Kyllä   Ei 
Ikä alle 18v 
  
Raskaus / tai sen epäily / tai imettää   
Kärsii rangaistusta vankilassa tai on asevelvollinen   
Vajaakykyinen (tutkimuslain vaatima kysymys)   
Kieltäytyy tutkimuksesta   
 
 
Sisäänottokriteerit Kyllä   Ei 
a) diagnoosi 
  
Pitkittynyt, krooninen poskiontelotulehdus ( kesto 3kk ajan tai pidempään) 
  
Toistuva poskiontelotulehdus (4 kertaa tai useammin vuoden pituisena ajanjaksona) 
  
Nenän ja/tai sivuonteloiden polyyppitauti 
  
Poskionteloiden tietokonekerroskuvauksessa sivuontelontulehduksen/polypoosin 
löydökset 
  




Tulossa sivuonteloiden endoskooppiseen leikkaukseen (FESS) 
  
Tulossa nenän tai sivuonteloiden polyyppien poistoon 
  
Tulossa muuhun  sivuontelotoimenpiteeseen:_____________________________________ 
  
 
Poskiontelotulehduksen riskitekijät Kyllä   Ei 
1. Allergiat  
(jos vastasitte ei, menkää suoraan kohtaan 3.) 
  
2. a) Jos allergia todettu, onko diagnosoitu:                   Missä:_____________________ 
Ihotestein: �           Verikokein: �         Oireiden perusteella: � 
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3. Onko teitä tutkittu epäillyn allergian takia, mutta allergiaa ei todettu 
  
4. Tupakoitteko, tai oletteko koskaan tupakoinut (jos vastasitte ei, menkää kohtaan 7) 
  
5. Jos olette joskus tupakoinut, mutta lopettanut: 
Montako vuotta on tupakoinnin lopettamisesta: _____________v 
Montako vuotta ehditte tupakoida:  _______________________v 
  
6. Jos edelleen tupakoitte: 
Montako vuotta olette tupakoinut: ________________________v 
Montako savuketta keskimäärin päivässä:__________________kpl 
 
 
7. Altistutteko ammatissanne, kotonanne tai harrastuksissanne jatkuvasti hengitysteitä 




8. Harrastatteko uintia:__________/ tuntia viikossa  tai    __________/ tuntia kuukaudessa 
 
 
9. Onko teillä todettu pitkäaikainen nenän limakalvojen ärsytystila (kutina, aivastelu)? Jos 
syy tiedossa, mikä: 
 
 
10. a) Onko teillä jatkuvaa/toistuvaa nenän vuotamista eteenpäin  
 
 
      b) Onko teillä jatkuvaa/toistuvaa nenän vuotamista taaksepäin ( ”takanuhaa”) 
 
 
      c) Onko teillä jatkuvaa/toistuvaa nenän karstaisuutta 
 
 
      d) Onko teillä jatkuvaa/ toistuvaa nenän tukkoisuutta 
 
 
11. Käytättekö pitkäaikaisesti (yli 2 viikon ajanjaksoja) nuhatippoja Mitä: 
 
 




      b) Oletteko käyttänyt kortisonivalmisteita suun kautta nenäoireisiinne:___kertaa/vuosi 
 
 
13. a) Onko teillä ollut pitkäaikaista ( yli 3kk) tai toistuvaa (yli 4 kertaa/ v.) poskiontelon 
tulehdusta. Minkä ikäisenä oireilu alkoi                                                               vuotiaana 
 
 
      b) Oletteko joutunut syömään antibioottikuureja nenän/poskiontelon tulehdukseen 




      c) Onko teitä koskaan aiemmin leikattu poskiontelotulehdusten (_____kertaa) tai 
polyyppien (_____kertaa) takia  alkaen __________________iässä 
 
 
Poskiontelotulehduksen riskitekijät Kyllä   Ei 
14. Onko teillä ollut korvatulehduksia >3 vuodessa/ liimakorva (alleviivaa oikea)____iässä 
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16. Onko teillä koskaan ollut nenämurtumia tai poskimurtumia ( alleviivaa mitä) 
 
 
17. Onko teillä todettu nenän alueen kasvaimia 
 
 
18. Onko teillä todettu ylähampaiden juuritulehduksia 
 
 
19. Onko teillä astmaa? (jos vastasitte ei, menkää kysymykseen 22) 
 
 
20. Jos astma todettu, onko diagnosoitu:    Oireiden perusteella: � 
Kotona tehtävin puhallustestein: �   Sairaalatutkimuksin: �  Missä:____________________      
 
 
21. Jos astma on todettu, onko se kausiluonteinen/ ympärivuotinen/rasitusastma  
Montako vuotta:_________v       Säännöllinen lääkitys  �      Montako lääkettä:_____kpl 
Montako lääkettä säännöllisesti: ______kpl 
 
 
22. a) Onko teillä ollut yli viikon kestäneitä nivelsärkyjä tai arkuutta käsissä tai jaloissa 
 
 
      b) Onko teille tehty tutkimuksia niveltulehdusten takia osastolla tai poliklinikalla 
 
 
      c) Onko teillä ollut jänteiden kiinnityskohtien tai jännetuppien tulehduksia 
 
 
23. a) Onko teillä silmien jatkuvaa kuivuutta tai roskan tunnetta 
 
 
      b) Joudutteko käyttämään silmien kostutustippoja/ vuotavatko silmänne 
 
 
      c) Onko teillä todettu silmien bakteeritulehduksia samanaikaisesti 
poskiontelotulehdusten kanssa:  mitä________________________________ 
 
 




      b) Onko teillä ollut runsaasti reikiä hampaissa ( kariesta eli hammasmätää) 
 
 
      c) Onko teillä herkästi ientulehdusta (parodontiittia) 
 
 
25. a) Onko teillä ollut toistuvaa tai kroonista nielurisatulehdusta ( angiinaa)  
 
 
      b) Onko teille tehty kitarisaleikkaus____v. iässä / nielurisaleikkaus ____v. iässä 
  
 
26. a) Onko teillä todettu valoyliherkkyyttä tai aurinkoihottumaa ( alleviivaa kumpaa) 
 
 
      b) Onko teillä taipumusta nokkosrokkoon (urtikariaan) 
 
 
      c) Saatteko mielestänne tavallista herkemmin mustelmia 
 
 
27. a) Onko teillä ollut toistuvia hiivasienitulehduksia (suussa, sukuelinalueella, jaloissa)  
           Antibioottikuureihin liittyen: �   Ilman antibioottikuureja: �    
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Appendix 2 
Tutkittavan potilaan kyselykaavake        Versio 1.0 / 2.1.2000 
 
 
Tutkittavan koodinumero: ________________ Tutkittavan nimikirjaimet: ____________ 
 
Tutkimus: 
Toistuvien ja kroonisten poskiontelotulehdusten immunologiset taustatekijät 
 
Sukupuoli      � nainen    � mies  Syntymävuosi: 19____           Ikä:____v 
 
Poissulkukriteerit Kyllä   Ei 
Ikä alle 18v 
  
Raskaus / tai sen epäily / tai imettää   
Kärsii rangaistusta vankilassa tai on asevelvollinen   
Vajaakykyinen (tutkimuslain vaatima kysymys)   
Ollut joskus toistuva poskiontelotulehdus (4 kertaa tai useammin vuoden pituisena 
ajanjaksona) 
  
Ollut joskus pitkittynyt, krooninen poskiontelotulehdus ( kesto 3kk ajan tai pidempään)   
Tämänkertaisen poskiontelotulehduksen oireiden kesto alle 7 vuorokautta   
Tämänkertaisen poskiontelotulehduksen oireiden kesto yli 28 vuorokautta   
Kieltäytyy tutkimuksesta   
 
 
Sisäänottokriteerit Kyllä   Ei 
Positiivinen poskiontelohuuhtelulöydös 
  




Poskiontelotulehduksen riskitekijät Kyllä   Ei 
1. Allergiat  
(jos vastasitte ei, menkää suoraan kohtaan 4.) 
  
2. Jos allergia todettu, onko diagnosoitu: 
Ihotestein: �           Verikokein: �         Oireiden perusteella: � 
  






Poskiontelotulehduksen riskitekijät (jatkuu) Kyllä   Ei 
APPENDICES
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4. Tupakoitteko, tai oletteko koskaan tupakoinut (jos vastasitte ei, menkää kohtaan 7) 
  
5. Jos olette joskus tupakoinut, mutta lopettanut: 
Montako vuotta on tupakoinnin lopettamisesta: _____________v 
Montako vuotta ehditte tupakoida:  _______________________v 
  
6. Jos edelleen tupakoitte: 
Montako vuotta olette tupakoinut: ________________________v 
Montako savuketta keskimäärin päivässä:__________________kpl 
 
 
7. Altistutteko ammatissanne, kotonanne tai harrastuksissanne jatkuvasti 








9. Onko teillä jatkuvaa nenän vuotamista ja/tai karstaisuutta 
 
 
10. Harrastatteko uintia 
Kuinka monta tuntia :__________/ viikossa     tai    __________/ kuukaudessa 
 
 








13. Onko teillä todettu nenäpolyyppeja 
 
 
14. Onko teillä todettu vino nenän väliseinämä (erottaa sieraimia toisistaan) 
 
 
15. Onko teillä koskaan ollut nenämurtumia 
 
 
16. Onko teillä koskaan ollut poskimurtumia 
 
 
17. Onko teillä todettu nenän alueen kasvaimia 
 
 
18. Onko teillä todettu ylähampaiden juuritulehduksia 
 
 
19. Onko teillä astmaa? (jos vastasitte ei, tämä oli viimeinen kysymys) 
 
 
20. Jos astma todettu, onko diagnosoitu: 
Kotona tehtävin puhallustestein: �   Sairaalatutkimuksin: �       Oireiden perusteella: � 
 
 
21. Jos astma on todettu: 
Montako vuotta:_________v       Säännöllinen lääkitys  �      Montako lääkettä:_____kpl 
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Tutkittavan koodinumero: ________________ Tutkittavan nimikirjaimet: ____________ 
 











Poissulkukriteerit Kyllä   Ei 
Ikä alle 2 tai yli 16v 
  








Sisäänottokriteerit ( vain pääleikkausindikaatio= kyllä) Kyllä   Ei 
Toistuvat äkilliset nielurisatulehdukset (yli 6/v. tai yli 3/v. kahtena peräkkäisenä vuotena), 
josta syystä tulossa nielurisaleikkaukseen (tonsillektomiaan) 
  
Krooninen nielurisatulehdus (krooninen tonsilliitti), josta syystä tulossa nielurisaleikkaukseen 
(tonsillektomiaan) 
  
Nielurisojen hyvänlaatuinen suurentuma ( tonsillahyperplasia), josta syystä tulossa 
nielurisaleikkaukseen (tonsillektomiaan) 
  








Huoltaja täyttää: Kyllä   Ei 
1.Onko lapsellanne ollut toistuvia ylähengitystietulehduksia?   
2.Onko lapsellanne ollut korvatulehduksia?   
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1-3: �           4-6: �           7-10: �           yli 10: �            
4.Onko lapsellanne ollut lääkärin toteamia poskiontelontulehduksia?   
5.Jos lapsellanne on  ollut poskiontelontulehduksia, kuinka monta niitä on ollut 
elämän aikana 
1-3: �           4-6: �           7-10: �           yli 10: �           jatkuva: �            
  
6. Onko lapsellanne jatkuvaa nenän vuotamista ja/tai karstaisuutta?   
7. Onko lapsellanne nenäverenvuototaipumusta?   
8. Onko lapsellanne herkästi mustelmataipumusta?   
9. Kuorsaako lapsenne?    
10. Onko lapsellanne selkeitä ja toistuvia unenaikaisia hengityskatkoksia?   
11. Onko lapsellanne lääkärin toteama allergia?  
       (jos vastasitte ei, menkää suoraan kohtaan 14) 
  
12. Jos allergia todettu, onko diagnosoitu: 
       Ihotestein: �           Verikokein: �         Oireiden perusteella: � 
  
13. Jos allergia todettu, mille lapsenne on allerginen: 
       ______________________________________________________________________ 
       Missä allergiatutkimukset on tehty?__________________________________________ 
  
14. Tupakoidaanko lapsen kotipiirissä?   
15. Onko lapsenne sairastanut rauhaskuumeen (mononukleoosin)?   
16. Onko muilla perheenjäsenillä toistuvia tai pitkäaikaisia nielurisatulehduksia?   
17. Onko lapsen hoitopaikassa tai ystäväpiirissä toistuvia tai pitkäaikaisia 
nielurisatulehduksia? 
  
18. Onko lapsenne päivähoidossa? Perhepäivähoito:�          Tarhahoito�   
19. Onko lapsellanne astma? (jos vastasitte ei, tämä oli viimeinen kysymys)   
20. Jos astma todettu, onko diagnosoitu: 
Kotona tehtävin puhallustestein: �   Sairaalatutkimuksin: �       Oireiden perusteella: � 
  
21. Jos astma on todettu: 
Montako vuotta:_________v       Säännöllinen lääkitys  �      Montako lääkettä:_____kpl 
Montako lääkettä säännöllisesti: ______kpl 
  
KIITÄMME MIELENKIINNOSTA TUTKIMUSTAMME KOHTAAN! 
APPENDICES
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We assessed whether complement and its factor C4 or abnormal immunoglo-
bulin levels are associated with chronic or recurrent rhinosinusitis. We used
multiple patient and control groups to obtain clinically meaningful data.
Adult chronic or recurrent rhinosinusitis and acute purulent rhinosinusitis
patients were compared with unselected adults and controls without previous
rhinosinusitis. Associated clinical factors were reviewed. Levels of immuno-
globulins, plasma C3, C4 and classical pathway haemolytic activity were anal-
ysed. C4 immunophenotyping was used to detect C4A and C4B deficiencies as
null alleles. Complement was up-regulated in rhinosinusitis. C4A nulls and
low IgA, IgG, IgG1, IgG2, IgG3 and IgG4 levels were all more common in
chronic or recurrent rhinosinusitis patients than in unselected and healthy
controls. We searched for relevant differences between the patient groups.
According to stepwise logistic regression analysis, nasal polyposis [odds ratio


























 0·017) and low levels of IgG4 together with either IgG1 or








 0·026) were more common in chronic
or recurrent rhinosinusitis than in acute rhinosinusitis patients. Isolated low
IgG subclasses had limited value in patient assessment. C4A null alleles are
associated with chronic or recurrent rhinosinusitis, potentially through their
effect on immune defence and inflammation control. Multiple clinical and
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Chronic rhinosinusitis has a prevalence of 2% and causes a
decrease in the quality of life similar to rheumatoid arthritis
[1]. The wide range of infectious and inflammatory disor-
ders of sinuses makes them common in general practice [2].
The immunological mechanisms leading to complicated
sinus infections remain enigmatic.
Immunoglobulin deficiencies predispose subjects to
treatment-refractory chronic or recurrent rhinosinusitis
(CRRS). IgA and IgG2 deficiencies in children may remain
asymptomatic or progress to severe common variable immu-
nodeficiency (CVID) [3,4]. In adult CRRS, low IgG4 levels
are seen only occasionally. The frequency of diminished
vaccination responses is not established [5,6]. Patients with
one or more subclasses absent are usually asymptomatic.
Those with low serum subclass levels often have elevated lev-
els of other subclasses [7]. Decreased levels are caused mainly
by regulatory disorders of antibody class-switching [8,9]. In
adult CRRS, mainly the levels of complement-fixing IgG1
and IgG3 subclasses are low [5,10–16]. Frequencies of low
immunoglobulin levels in the general population and acute
rhinosinusitis patients are unknown, making clinical evalu-
ation difficult [4,7].
Complement participates in opsonization, chemotaxis,
leucocyte activation and direct killing of microbes [17]. It
augments antibody formation and the development of
immunological memory [18]. Recurrent rhinosinusitis is
